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Abstract 
The Global Assessment of Severity of Epilepsy (GASE) Scale is a single-item, 7-point 
global rating scale designed for neurologist-report of overall severity of epilepsy in 
children. Preliminary evidence suggested it may be valid and reliable for research and 
clinical use. Data from the Health-Related Quality of Life in Children with Epilepsy 
Study (HERQULES) was analyzed to evaluate validity, stability, and responsiveness of 
GASE scores. Spearman’s Rho indicated that GASE was moderately correlated with key 
aspects of epilepsy but weakly correlated with parents’ perceptions of child health. 
Frequency and intensity of seizures and interference of epilepsy or drugs with daily 
activities were most strongly correlated with GASE. Intra-class correlation coefficients 
(ICC) provided modest evidence that GASE could detect stability. Distribution- and 
anchor-based indices suggested that GASE was responsive to changes in clinical criteria. 
Results support the construct validity, stability, and responsiveness to change of the 
GASE Scale in children with epilepsy. 
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CHAPTER 1  
INTRODUCTION 
1.1 Introduction 
Assessment of the severity of epilepsy is important for both treatment and research 
aiming to improve health-related quality of life (HRQL). Characterizing the severity of 
epilepsy in individuals assists clinicians in decision-making and monitoring treatment, 
while facilitating communication and counselling for patients and families. It enables 
researchers to test and compare the effectiveness of interventions within and across 
studies. While advances in neuroscience have prompted the revision of past definitions 
and classifications of epilepsy, the development of health measurement tools that provide 
valid and reliable data continues to be a challenge for both researchers and clinicians. 
Multiple tools for measuring the severity of seizures, syndromes, and epilepsy have been 
developed but there is no universally accepted standard scale of severity (Thurman et al., 
2011). The severity of epilepsy is predominantly assessed with measures of the severity 
of seizures. These measures fail to address other dimensions of epilepsy such as disability 
due to disease and side effects of antiepileptic drugs (AEDs). Although there is some 
evidence to support limited use of these scales, most existing scales are limited by the 
difficulty of use and inadequate evidence supporting validity, reliability, and 
responsiveness to change. 
1.2 Purpose and Rationale 
The International League Against Epilepsy (ILAE) reviewed epilepsy-related severity 
assessment instruments and emphasized the importance of broader assessment tools to 
better capture the severity of epilepsy. In its review, the ILAE describes the Global 
Assessment of Severity of Epilepsy (GASE) Scale as demonstrating reliability and 
validity (Thurman et al., 2011). The GASE Scale is a single-item, 7-point global rating 
scale. It was developed as a clinician-report measure to assess the overall severity of 
epilepsy in children and to provide a simple and efficient tool to capture the 
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multidimensional nature of epilepsy. This thesis aims to extend the assessment of the 
measurement properties of the GASE Scale. 
Severity of illness is a complex concept that involves biology, physical function, and the 
psychosocial impact of disease (Stein et al., 1987). Numerous factors such as the purpose 
of an instrument, the viewpoint (physician, patient, and caregiver), time frame, and 
population of interest all influence the interpretation of the assessment of severity 
(Speechley et al., 2008). Validation of measures involves an ongoing process of obtaining 
repeated evidence to verify its accuracy and reliability in measuring its intended construct 
(Streiner and Norman, 2008, pp.250-2). 
To improve confidence in the GASE Scale, it is important that multiple analyses, 
different criteria, and methods can support the central theory that the scale measures the 
overall severity of epilepsy in children. Within the realm of validating theories for 
measurement tools, construct validity has become a well-established concept and 
encompasses the specific tests of validation (Smith, 2005). To further assess the quality 
of information collected by the GASE Scale beyond preliminary evidence that supported 
its validity and reliability (Speechley et al., 2008), this thesis project aims to assess the 
construct validity, stability, and responsiveness to change in severity of the GASE in a 
sample of Canadian children. Previous preliminary research provided evidence to support 
the GASE Scale’s face and content validity, convergent validity, inter-rater and test-retest 
reliability using hypothetical case scenarios, and discriminative properties for three types 
of epilepsy syndromes (Speechley et al., 2008). Continuing this process of validation 
should involve the following analyses, among others: evaluation of construct validity, 
both convergent and discriminant using primary clinical data in the course of studies in 
which the GASE was used; assessment of the inter-rater and test-retest reliability in a 
clinical sample; comparison of this physician-rated scale with other commonly used 
clinical measures in childhood epilepsy; and assessment of the responsiveness of the 
GASE Scale to clinically meaningful changes in severity of epilepsy. 
This thesis builds on the previous work that evaluated the convergent validity of the 
GASE Scale in a cross-sectional analysis of 134 children (Speechley et al., 2008), by 
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examining a larger sample of children treated at multiple centres across Canada (n = 373) 
with newly-diagnosed epilepsy in a two-year longitudinal research study assessing the 
course and determinants of HRQL. Expanding the scope of construct validation for the 
GASE Scale, new comparisons are introduced with several physician-rated clinical 
aspects of epilepsy not previously evaluated, as well as the parents’ perception of their 
children’s health. In addition to construct validity, this thesis will provide critical new 
information on the stability of the scale, and how it responds to clinically meaningful 
changes in severity over time, which has not been assessed previously. 
Although construct validation has been reconceptualized to include all forms of validity 
testing (Streiner and Norman, 2008, pp.251-2), in the interest of clarity, this thesis will 
continue to refer to the specific types of validity. 
1.3 Thesis Objectives 
This thesis has three main objectives: 
1. To assess the construct validity of the GASE Scale; 
2. To assess the stability of the GASE Scale; 
3. To assess the responsiveness of the GASE Scale to changes in severity of 
epilepsy.  
For each of these objectives, several hypotheses will be tested.  
Hypotheses associated with Objective 1: To assess the construct validity of the 
GASE Scale: 
a) GASE scores will be correlated with several clinical aspects of epilepsy rated by 
neurologists. These correlations are predicted to be at least moderate (r ≥ 0.3), 
given that the GASE Scale was developed to take into account all aspects of a 
patient’s epilepsy (Speechley et al., 2008).  
 “Frequency of seizures” will be the clinical aspect with the strongest 
correlation with GASE scores, given its importance in the assessment 
of the severity of epilepsy in past research (Cramer and French, 2001, 
O'Donoghue et al., 1996, Speechley et al., 2008). 
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b) GASE scores will be correlated at least moderately (r ≥ 0.3) with the “total 
number of AEDs” reported by neurologists, given that patients with worse seizure 
control and adverse side effects of AEDs are reported to have been treated with a 
greater number of medications (Moran et al., 2004). 
c) GASE scores will indicate more severe epilepsy for children who have 
experienced convulsive status epilepticus (CSE) than for those who have not, 
since the condition is recognized as being associated with significant morbidity 
and mortality (Raspall-Chaure et al., 2006, Martinos et al., 2013). 
d) GASE scores will indicate less severe epilepsy for children whose seizures are 
exclusively nocturnal, since seizures that occur exclusively during sleep generally 
have better prognosis and tend to be less disruptive than seizures during the day 
(Bazil, 2003, Ekizoglu et al., 2011). 
e) GASE scores will be correlated with parents’ perception of child health. The 
correlation will be at least moderate (r ≥ 0.3) with GASE scores indicating more 
severe epilepsy associated with parents reporting children’s health as poorer, 
given that parents’ perceptions of their children’s health are likely to reflect recent 
status of epilepsy. 
Hypothesis associated with Objective 2: To assess the stability of the GASE Scale: 
a) In patients for whom neurologists’ reports of key clinical aspects of epilepsy and 
a composite score indicate stability in the patient’s epilepsy over a period of 6 
months, GASE scores will remain stable over the same time period. 
b) In patients whose parents’ reports of child health status indicate stability in the 
patient’s epilepsy over a period of 6 months, GASE scores will remain stable 
over the same time period. 
Hypotheses associated with Objective 3: To assess the responsiveness of the GASE 
Scale: 
Distribution-based methods (internal responsiveness):  
a) The GASE Scale will be able to detect statistically significant changes in the 
severity of epilepsy over time (from baseline to 6, 12, and 24 months post-
diagnosis).  
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Anchor-based methods (external responsiveness): 
b) Change in severity of epilepsy reported using the GASE Scale over a period of 
12 months will be correlated with neurologists’ reports of changes in key clinical 
aspects of epilepsy and a composite score of the aspects over the same time 
period.  
c) Change in severity reported using the GASE Scale over a period of 12 months 
will be correlated with changes in parents’ perceptions of child health status over 
the same time period. 
d) In patients for whom neurologists’ reports of key clinical aspects of epilepsy and 
the composite score indicate change in the patient’s epilepsy over a period of 12 
months, common responsiveness statistics will show that GASE scores also 
change over the same time period. 
e) In patients whose parents’ reports of child health indicate change in the patient’s 
epilepsy over a period of 12 months, common responsiveness statistics will show 
that GASE scores also change over the same time period. 
1.4 Overview on Epilepsy 
Epilepsy is one of the most common neurological disorders in the world. The World 
Health Organization (WHO) estimates that 2.4 million people are newly diagnosed each 
year and that a total of 50 million cases were estimated in 2005. Epilepsy can affect any 
person regardless of age, sex and race. However, children and adolescents suffer the 
greatest impact as 50% of diagnoses occur prior to adulthood (World Health Organization 
et al., 2005).  
Known to Hippocrates of the ancient Greeks and documented as early as the Babylonians 
over 3000 years ago, defining and classifying epilepsy have been important challenges in 
the history of understanding the condition (World Health Organization et al., 2005). 
The term epilepsy was conceptually defined in 2005 by the ILAE and the International 
Bureau for Epilepsy (IBE) as “a disorder of the brain characterized by an enduring 
predisposition to generate epileptic seizures and by the neurobiologic, cognitive, 
psychological, and social consequences of this condition”. This definition of epilepsy 
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required the occurrence of at least one epileptic seizure (Fisher et al., 2005). An epileptic 
seizure was defined as “a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain” (Fisher et al., 2005). In 2014, the 
definition of epilepsy was revised by the ILAE Task Force with consultation from the 
international epilepsy community to redefine the operational definition for clinical 
purposes (Fisher et al., 2013). The report broadens the definition and clearly defines 
epilepsy as a disease in contrast to the traditional reference to epilepsy as a disorder or 
representing a multitude of brain disorders (Fisher et al., 2014). The following is the 
official new definition for seizures and epilepsy:  
Epilepsy is a disease of the brain defined by any of the following conditions: 
1. At least two unprovoked (or reflex) seizures occurring > 24 hours apart; 
2. One unprovoked (or reflex) seizure and a probability of further seizures 
similar to the general recurrence risk (at least 60%) after two unprovoked 
seizures, occurring over the next 10 years; 
3. Diagnosis of an epilepsy syndrome. 
Epilepsy is considered to be resolved for individuals who had an age-
dependent epilepsy syndrome but are now past the applicable age or those 
who have remained seizure-free for the last 10 years, with no seizure 
medicines for the last 5 years (Fisher et al., 2014). 
1.4.1 Classification 
Since 1960, the ILAE has been classifying epileptic seizures and syndromes, with 
publications in 1981 for the classification of seizures, and 1989 for the classification of 
epilepsies and epileptic syndromes (Berg et al., 2010). Several revisions to terminology 
and concepts as recommended by the Commission on Classification and Terminology of 
the ILAE (CCTILAE) from 2005 to 2009 were published by Berg et al. (2010), noting 
that significant advances in basic and clinical neurosciences have resulted in greater 
insight into epilepsy and seizures, necessitating regular changes to previous classification 
systems. Standard classification of epilepsy is not only important for clinical and research 
communication, but also for diagnoses and descriptions relating to specific medications 
and treatment (CCTILAE, 1981).  
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The 1981 International Classification of Epileptic Seizures (ICES) is based on clinical 
features using electroencephalograms (EEGs) and video recordings as analyzed by expert 
members of the CCTILAE (CCTILAE, 1981). Seizures are classified into categories of 
partial (focal and local), generalized (convulsive or nonconvulsive) and unclassified 
epileptic seizures, with further detailed sub-classification within these categories 
(CCTILAE, 1981). Partial seizures are recognized by the exclusive initial activation of 
neurons in a single cerebral hemisphere, whereas generalized seizures activate neurons 
simultaneously in both hemispheres. The further classification of partial seizures is based 
primarily on the extent of impaired consciousness, while generalized seizures commonly 
impair consciousness and are thus further classified mainly according to differences in 
EEG characteristics such as patterns of electrical activity (CCTILAE, 1981). 
The 1989 International Classification of Epilepsies and Epileptic Syndromes (ICE) was 
created to supplement ICES (CCTILAE, 1989). Similar to ICES, classifications in ICE 
were decided through the study of clinical features, EEGs and video recordings. An 
epileptic syndrome is characterized by a specific collection of signs and symptoms and is 
determined according to criteria such as the type of seizures, severity, age of onset, 
etiology, and other electroclinical characteristics. ICE consists of four categories: 
localization-related (focal, local, and partial), generalized, undetermined (focal and 
generalized), and special syndromes. Syndromes are further subdivided according to 
idiopathic, symptomatic, and cryptogenic conditions (CCTILAE, 1989). However within 
the past decade, the CCTILAE has recommended the replacement of these terms to 
reflect etiology with “genetic”, “structural and metabolic”, and “unknown cause” (Berg et 
al., 2010). Thurman et al. (2011) note that this broader classification is more flexible to 
different study purposes and future advances in etiological research. 
A revised classification system for seizures was created in 2006 by the Core Group of the 
Task Force on Classification and Terminology of the ILAE and is summarized in Table 
1.1 (Engel, 2006). The updated system reclassifies seizure types into self-limited epileptic 
seizures and status epilepticus. There are three main categories for self-limited epileptic 
seizures: generalized onset, focal onset, and neonatal seizures. Generalized onset seizures 
are further subdivided into five categories: seizures with tonic and/or clonic 
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manifestations, absences, myoclonic seizure types, epileptic spasms, and atonic seizures. 
Focal onset seizures are characterized by differences in the structure, site, and spread of 
seizure-induced disruption in neuronal function (Engel, 2006). Therefore, they are 
subdivided into the four categories: local, with ipsilateral propagation to, with 
contralateral spread to, and secondarily generalized seizures. The unique features of 
neonatal seizures enable further classification. Status epilepticus is further classified into 
nine categories according to the associated mechanisms of initiation, spread and 
termination, as well as factors affecting maturation and future structural or functional 
brain disturbances (Engel, 2006). 
In the 2011 ILAE Epidemiology Commission Report on “Standards for Epidemiologic 
Studies and Surveillance of Epilepsy”, Thurman et al. (2011) suggested a new matrix for 
classifying seizures that was flexible to cases where information is unavailable or 
unclear, particularly EEG data. The proposed system classifies seizures according to two 
criteria: onset (generalized, focal, and undetermined) and predominant ictal features 
(motor, nonmotor, and unknown). 
Although the classification of epilepsy syndromes was recommended by Berg et al. 
(2010) to reflect etiology, both Engel (2006) and Berg et al. (2010) acknowledge that 
updating the classification of syndromes is still a work in progress and that age at onset is 
another example of how epilepsy syndromes can be organized. The classification of all 
recognized epilepsy syndromes according to age of onset and related conditions are 
outlined in Table 1.2. 
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Table 1.1: Epilepsy seizure classification.  
Reproduced with permission from Table 1 in Engel (2006), Copyright © 2006 John 
Wiley and Sons (Appendix C). 
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Table 1.2: Epilepsy syndrome classification.  
Reproduced with permission from Table 3 (Electroclinical syndromes and other 
epilepsies) in Berg et al. (2010), Copyright Wiley Periodicals, Inc. © 2010 
International League Against Epilepsy (Appendix D). 
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1.4.2 Prevalence and Incidence 
According to the WHO, epilepsy is among the top three conditions reported in primary 
health care settings around the world (Wiebe et al., 2009). With a substantial global 
burden of disease, the prevalence of epilepsy was estimated to be 65 million people 
worldwide in 2010 (Thurman et al., 2011). The WHO estimates that in developed 
countries, the incidence is approximately 40 to 70 new cases each year per 100,000 
persons, while the incidence rate in developing countries is approximately double (World 
Health Organization, 2012).  
Although the reported rates of disease vary across studies due to differences in case 
definitions and research methods, in Canada the prevalence of epilepsy is approximately 
600 cases per 100,000 persons. For children and adolescents, the incidence in Canada has 
been reported to range between 21 and 118 cases per 100,000 persons, paralleling rates in 
the United States and other industrialized countries (Wiebe et al., 2009). 
The negative impact of epilepsy is expressed through increased economic costs, greater 
prevalence of psychosocial outcomes, higher rates of injury, poorer quality of life, and 
higher rates of mortality than in the general population (Wiebe et al., 2009). 
1.4.3 Etiology 
Following the classification scheme recommended by the CCTILAE in relation to the 
subcategories of epileptic syndromes, there are currently three main types of causes 
defined by the ILAE, namely, genetic, structural and metabolic, and syndromes with 
unknown cause (Berg et al., 2010). Often the cause of epilepsy and seizures is 
multifactorial (Bell and Sander, 2001), involving complex factors such as the 
environment, genetics, comorbidity, and other physiologic functions (Hart and Sander, 
2008). Multiple precipitating factors also influence the likelihood of epileptic seizures, 
such as head injuries, sleep deprivation, substance abuse, and stress. The etiology of 
epilepsy varies by risk factors such as age and type of seizures. In infants, epilepsy may 
result from hypoxia, perinatal intracranial trauma, disruptions in metabolism, infection, 
and brain malformations (Hart and Sander, 2008). The cause of epilepsy is harder to 
determine in children and adolescents, however, with approximately 70% of seizures 
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considered idiopathic (Cowan et al., 1989) and attributed to a genetic predisposition (Hart 
and Sander, 2008). Adult onset epilepsy involves the same causes, in addition to brain 
tumours and cerebrovascular disease as the most common causes over the age of 30 (Hart 
and Sander, 2008). However, in developing nations, parasitic, bacterial, and viral 
infections are the most important etiological factors (Senanayake and Román, 1993). 
The complex pathophysiologic processes leading to the development of epileptic seizures 
and epilepsy may be induced by etiological risk factors causing mutations in ion-
channels, focal lesions, neurogenesis, neuronal loss, structural reorganization of neuronal 
circuitry, and changes in the neuronal microenvironment (Chang and Lowenstein, 2003). 
Since most cases of epilepsy are idiopathic, the exact molecular, chemical and genetic 
mechanisms are unclear (Chang and Lowenstein, 2003). 
1.4.4 Clinical Aspects of Childhood Epilepsy 
The manifestation of epilepsy and epileptic seizures varies according to individual 
differences in brain maturity, neuronal activity, confounding disease, medications, and 
several other factors (Fisher et al., 2005). However, following the ICES (CCTILAE, 
1981) and the ICE (CCTILAE, 1989), common signs and symptoms have been used to 
categorize different types of epileptic seizures and syndromes. This classification system 
details identifiable clinical aspects of epilepsy, such as the impairment of consciousness 
at seizure onset during a complex partial seizure (Engel, 1991).  
At the onset of a seizure, normal sensory, motor and autonomic functions are typically 
interrupted (Fisher et al., 2005). Sensory distortions may arise as single sensations such 
as visual hallucinations or as a complex experience of multiple sensory systems. Changes 
in the nervous system can be expressed as impaired consciousness and behaviour, as well 
as changes in emotional state such as fear and elation. Distortions in memory manifest as 
both positive and negative symptoms, whereas cognitive deficits can negatively affect 
abilities such as attention and speech. As described previously in Section 1.4, epilepsy is 
officially diagnosed in three circumstances: when a patient experiences at least two 
unprovoked seizures that occur > 24 hours apart, when the recurrence rate of further 
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unprovoked seizures is high, and when patients are diagnosed with an epilepsy syndrome 
(Fisher et al., 2014).  
The years between the ages of 2 and 12 have been described as a phase where the 
development of cognitive and social skills is crucial. The effects on development define 
the categories of “benign”, “intermediate”, and “catastrophic” epilepsy in childhood. 
Benign epilepsy involves mild infrequent seizures without cognitive and psychosocial 
effects. Catastrophic epilepsy involves a high frequency of seizures and associated 
injuries with permanent effects on cognitive and social development. It is often resistant 
to medication and symptoms can cause significant social barriers such as the need to 
continually wear protective equipment. Some benign epilepsies are clearly identifiable, 
such as benign rolandic epilepsy with typical features, genetic etiology, and excellent 
prognosis. However, as benign occipital epilepsy demonstrates, they may also be 
complex with variable features, unknown etiology, and indeterminate prognosis. 
Intermediate epilepsies include childhood absence epilepsy, epilepsies characterized by 
cryptogenic partial seizures, and generalized epilepsy with febrile seizures plus (GEFS+) 
(Camfield and Camfield, 2002). The clear categorization of these epilepsies into “benign” 
and “catastrophic” is complicated by the variation in response to medication, as well as 
presence and absence of cognitive and learning problems. Catastrophic childhood 
epileptic syndromes include continuous spike-wave in slow sleep (CSWS) disorder, 
Landau-Kleffner syndrome, Lennox-Gastaut syndrome, and Myoclonic-astatic epilepsy 
(Camfield and Camfield, 2002). 
1.4.5 Prognosis and Treatment 
Prognosis in epilepsy depends on factors such as etiology, patient age, seizure type, 
number of seizures, and other characteristics that influence treatment (Bell and Sander, 
2001). With no cure for epilepsy, medical treatment is primarily designed to control and 
eliminate seizures (Kohrman, 2007). However, it is now widely accepted that optimizing 
HRQL is an equally important goal (Speechley, 2013). 
Bell and Sander (2001) detail four groups that help to categorize prognosis. “Excellent 
prognosis” is defined by few seizures and a high potential for spontaneous remission. 
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“Good prognosis” describes seizures that are controlled by AEDs and remission that is 
usually permanent. “AED-dependent prognosis” is when the long-term use of AEDs is 
required to suppress seizures, whereas “bad prognosis” is when intensive AED treatment 
is unable to control seizures. In the clinical setting, these prognostic groups are no longer 
in common use due to difficulties in its practical application (Bell and Sander, 2001). 
Through treatment but without the long-term use of AEDs, approximately 70% of 
patients become seizure-free. However, AEDs are required for seizure control in 
approximately 10% to 15% of patients, and 15% to 20% of patients are unable to 
suppress seizures even with intensive AED therapy. Despite the approval of over 15 anti-
seizure medications by the US Food and Drug Administration, the use of a single 
medication at a time is preferred in treating epilepsy to reduce the number of adverse side 
effects (Kohrman, 2007).  
Common side effects of AED use in children include hyperactivity, somnolence, weight 
changes, and skin rashes (Greenwood, 2000, Kohrman, 2007). AEDs typically function 
by increasing the inhibition and reducing the excitability of membranes (Engel, 1991). 
The general effect on cerebral function is therefore nonspecific and leads to adverse side 
effects (Engel, 1991). Newer medications are not always more effective than older drugs, 
however, they often have fewer known side effects (Kohrman, 2007). Alternative 
therapies for treating epilepsy include the ketogenic diet, vagus nerve stimulation, 
experimental implantable devices, and surgery (Kohrman, 2007). 
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1.5 Overview of Thesis 
The remaining chapters of this thesis are organized as follows:  
Chapter 2 briefly describes the concept and measurement of severity and single-item 
rating scales, followed by a review of the psychometric properties of existing scales for 
the measurement of the severity of seizures, syndromes, and epilepsy. Chapter 3 provides 
relevant definitions and an overview of psychometric properties of measurement scales. 
This chapter also describes the research methodology including data source, study 
population, measures, and data analysis strategies specific to each objective. Chapter 4 
reports the sample characteristics and results of the current study, while Chapter 5 
presents a detailed discussion of the study results, strengths and limitations of the study, 
and future directions for the GASE Scale.  
 
16 
 
 
 
CHAPTER 2  
LITERATURE REVIEW 
2.1 The Concept and Measurement of Severity 
There are many ways to define severity for both clinical and health research goals. Stein 
and colleagues (1987) explain that severity is not a fixed concept and that different types 
of severity represent distinct constructs and characteristics. They describe severity as a 
broad abstract construct that can represent characteristics of a biological defect, amount 
of illness or disability, impact on quality of life, and social, emotional or financial burden. 
To help define the concept of severity, a framework was developed that outlines three 
inter-related constructs related to intrinsic biological severity: physiological or 
morphological severity, functional severity, and burden of illness. These types of severity 
interact to form the larger overall concept of severity of chronic illness (Stein et al., 
1987). 
Measuring severity involves specifying a dimension of illness along a spectrum and using 
proxies to quantify the clinical manifestations of interactions among biological, genetic, 
and environmental determinants. To quantify aspects of the framework, proxies 
measuring physiological and morphological severity use laboratory and anatomical 
reports while measures of functional severity assess aspects of health related to regular 
daily function, such as the number of days spent in bed or cognitive disability due to 
disease. The burden of illness on families and society incorporates the financial, 
emotional, and social dimensions of severity (Stein et al., 1987).  
Severity may derive from different aspects of life and health depending on the 
perspective of the clinician, patient, or family. Therefore, the objectives and perspective 
of a study, the type of illness or disability, time frame, and the population of interest will 
determine the criteria for defining and measuring severity. Severity can be measured 
through direct observations of symptoms and behaviours or indirectly using existing 
records and third party judgements. This variety is reflected in the many different severity 
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scales developed for different types of disease depending on the study objectives, 
population, and design (Stein et al., 1987).  
2.2 Single-item Rating Scales 
Single-item rating scales are widely used in research and clinical applications as an 
alternative to multi-item measures. While multi-item measures contain several items to 
evaluate the different dimensions of a construct, single-item measures represent an entire 
concept in a single, global question and are open to consider every dimension influencing 
the assessment of a phenomenon (Gardner et al., 1998, Patrician, 2004). Common single-
item scaling methods include the visual analog scale (VAS), the unipolar adjectival scale, 
the bipolar Likert scale, and graphical representational scales such as the face scale which 
uses pictures to show varying degrees of unhappiness, pain or distress (Streiner and 
Norman, 2008). As they are easy to administer, reduce costs, and require less time to 
complete, single-item measures impose minimal burden on patients and physicians 
(Patrician, 2004). However, since the objectives and requirements of a study determine 
which type of measure to use, in situations where researchers are interested in 
differentiating the main dimensions under evaluation or identifying a detailed source of 
change in longitudinal studies, multi-item measures are more suitable (Youngblut and 
Casper, 1993, Patrician, 2004).  
Despite thorough debate over the utility of single-item rating scales, there is evidence that 
in certain circumstances multi-item measures are not always better (Gardner et al., 1998). 
Single-item measures were reported to effectively assess health status (DeSalvo et al., 
2006), quality of life (Zimmerman et al., 2006), psychological well-being (Youngblut and 
Casper, 1993, Zimmerman et al., 2006), medication adherence (Kalichman et al., 2009), 
and other non-health related concerns such as job satisfaction (Wanous et al., 1997). 
Clinicians’ ratings on single-item scales have also demonstrated validity in many 
domains of health, including sedation (Weinert and McFarland, 2004), quality of life and 
side effects of chemotherapy (Coates et al., 1983a, Coates et al., 1983b, Coates et al., 
1990), anxiety with myocardial infarction (De Jong et al., 2005), bladder condition 
(Coyne et al., 2006), physical activity (Iwai et al., 2001), dental anxiety (Neverlien, 
1990), severity of dyspepsia symptoms (Veldhuyzen van Zanten et al., 2006), quality of 
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life and health in epilepsy (Stavem et al., 2000, Stavem et al., 2001), and severity of 
seizures (Carpay et al., 1996). 
2.3 Measurement of Severity of Seizures and the Severity 
of Epilepsy 
An ongoing challenge for clinicians and researchers is the measurement of the severity of 
epilepsy. Although multiple measurement tools have been developed, there is no 
universally accepted standard severity scale (Thurman et al., 2011). The objectives of a 
study typically inform the choice of particular measure to use and studies often employ 
more than one measure.  
In clinical trials measuring the efficacy of new AEDs, the frequency and severity of 
seizures are important outcome measures (Baker et al., 1998a). However, the majority of 
existing scales emphasize only the assessment of the severity of seizures. These ratings 
scales are similar in the method of evaluation used, usually an interview or questionnaire, 
but they prioritize different clinical characteristics and sources for assessment, such as the 
clinician’s viewpoint or the patient’s perspective (Thurman et al., 2011). 
The ILAE “Standards for Epidemiologic Studies and Surveillance of Epilepsy” (Thurman 
et al., 2011) provides a table that identifies common examples of standardized “epilepsy-
related severity assessment instruments” developed for clinical trials. Three categories of 
measures are listed. There are six “Seizure Severity Measures”: the Seizure Frequency 
Scoring System (SFSS); the Veterans Administration Seizure Frequency and Severity 
Rating Scale (VA); the National Hospital (Chalfont) Seizure Severity Scale (NHS3); the 
Occupational Hazard Scale (OHS); the Liverpool Seizure Severity Scale (LSSS); and the 
Hague Seizure Severity Scale (HASS). There is one “Syndrome Severity Measure” listed, 
namely the Epilepsy Syndrome Severity Scores- Child (ESSS-C). There is only one 
measure listed as an “Epilepsy Severity Measure”, the Global Assessment of Severity of 
Epilepsy (GASE) Scale. 
The following review outlines four of the measures listed by the ILAE that are specific to 
the assessment of the severity of epilepsy seizures, syndromes, and overall illness. Two 
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instruments that were designed for a specific purpose, that is, the SFSS assessing patients 
undergoing surgery (Rodgers et al., 2012) and the OHS assessing the degree of social 
impairment affecting work suitability (Cramer and French, 2001) are not described here. 
Other scales that evaluate specific forms of epilepsy such as the Early Childhood 
Epilepsy Severity Scale (E-Chess) (Humphrey et al., 2008) assessing childhood tuberous 
sclerosis are not reviewed here either. The Seizure Severity Questionnaire (SSQ) is also 
included in this review under the heading of “Measures of Severity of Seizures” for its 
assessment of the severity of seizures. 
2.4 Measures of Severity of Seizures 
2.4.1 Veterans Administration Seizure Frequency and Severity 
Rating Scale (VA) 
Developed by the Veterans Administration Cooperative Study Group in 1978 and revised 
in 1985, the VA Scale was designed for use in clinical trials to compare the effects of 
anti-epileptic drugs (AEDs). Over more than a decade, 1100 patients with newly 
diagnosed epilepsy were recruited to participate in two multicenter studies (Cramer, 
2001) assessing the efficacy of four common anticonvulsant drugs in the USA (Wijsman 
et al., 1991). The VA Scale is an interviewer-administered assessment (Baker et al., 
1998a) that relies on the recall and diaries of patients to inform the severity score 
(Cramer, 2001). Clinicians interview patients together with individuals who have 
observed the seizures. The scale is composed of three sections each focusing on one of 
the three types of partial-onset seizures: simple, complex, and secondarily generalized. 
Incorporating both the levels of frequency and the severity of seizures, the sections 
contain similar questions. Each section score is scored based on seizure type and 
frequency, followed by modifications according to the circumstances surrounding a 
seizure such as a warning sign. Section scores are then combined into a final composite 
score (Cramer, 2001). The composite score enabled a simple evaluation and comparison 
of AED outcomes in the VA Cooperative studies (Wijsman et al., 1991).  
Validity and Reliability. Although the developers of the VA Cooperative Studies reported 
results comparing scores on the VA Scale for patients using the four most commonly 
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used AEDs, they did not report any results of specific psychometric testing for the VA 
Scale (Cramer, 2001).  
An independent assessment of the inter-rater reliability of the composite VA score as an 
indicator of clinical severity was conducted in the Netherlands using 24 consecutive 
patients 15 years of age and older selected at random from out-patient clinics with two 
successive interviews conducted separately by the patient’s clinician and one of the study 
authors using the VA Scale. The results indicated moderate inter-rater reliability 
(Wijsman et al., 1991). Further validity testing of the composite score conducted in 47 
consecutive patients produced results indicating acceptable construct validity (Wijsman 
et al., 1991). 
Responsiveness. The responsiveness of the VA Scale is unclear, as the initial VA 
Cooperative studies comparing the treatment effects of four AEDs did not agree on the 
sensitivity of the scale. Developers were unable to determine whether the finding of no 
significant difference among treatment groups was due to the scale’s inability to detect 
change or the general equivalence among the AEDs. However, the second VA trial 
reported a significant difference in scores between patients taking carbamazepine (CBZ) 
and valproate (VPA) (CBZ mean: 6.2 versus VPA mean: 2.0, p = 0.04) (Cramer and 
French, 2001). 
Summary. Although clinicians completed each interview within the 20 minute time frame 
for regular consultation during both prospective studies (Wijsman et al., 1991), the 
scoring system was found to be complex, thus limiting its widespread use (Cramer, 
2001). While the VA Scale is recognized as an adequate tool for overall assessment based 
on a review of the evidence, caution has been advised regarding the extent to which the 
scale can be used to measure changes in seizure severity based on its lack of sensitivity 
reported by the initial VA Cooperative Studies (Cramer and French, 2001).  
2.4.2 National Hospital (Chalfont) Seizure Severity Scale (NHS3) 
The Chalfont Seizure Severity Scale, first described by Duncan and Sander (1991), was 
designed to evaluate the severity of seizures in AED clinical trials. Consisting of 
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weighted scores for 11 clinical features affecting the severity of seizures, the Chalfont 
scale is a patient- and observer-based scale that can accommodate evaluation of patients 
with several types of seizures. When administered by health professionals, the scale can 
be completed within a few minutes. Content of the scale was determined through 
interviews with 50 recruited patients and their families at an epilepsy clinic in the United 
Kingdom (Duncan and Sander, 1991). Although the age and sex of patients were not 
described by Duncan and Sander (1991), Baker et al. (1998a) indicated that the 1996 
revised version of the Chalfont scale renamed the National Hospital Seizure Severity 
Scale (NHS3) was intended for adults. 
Based on the results of a study on the AED tiagabine (Duncan and Sander, 1991), 
suggesting poor responsiveness to change, there were substantial revisions to create the 
NHS3 (O'Donoghue et al., 1996). 
Similar to the approach of the VA Scale, the NHS3 involves responses from patients and 
relatives who have witnessed the seizures (Baker et al., 1998a). However, unlike the VA 
scale, evaluated seizures are not restricted to three types and a single 7-item system is 
used for assessment (Cramer, 2001). The NHS3 is adapted from the Chalfont scale with 
fewer seizure-related factors and a simpler scoring system where all seven items have 
equal weight except for a question on warnings prior to seizures (O'Donoghue et al., 
1996). 
Validity and Reliability. The NHS3 was found to have sufficient inter-rater and test-retest 
reliability for use in AED trials when data were analyzed for groups of individuals, but 
not for single patient data based on a study of 87 consecutive adult patients (45 males and 
42 females) with a median age of 31 years (range: 27 to 44 years), accompanied by their 
relatives from an epilepsy clinic at a tertiary referral centre (O'Donoghue et al., 1996).  
There is also evidence of construct validity of the NHS3 based on two experiments (n1 = 
80 and n2 = 50) that asked patients to rank the severity of five sample seizure types 
presented on cards for comparison with a ranking determined by the NHS3 (weighted 
kappa = 0.82 signifying very good agreement) (O'Donoghue et al., 1996). 
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Responsiveness. Studies using the NHS3 did not provide evidence to support the 
responsiveness of the scale, which suggests that the drugs either did not affect the 
severity of seizures or the scale was incapable of detecting change (Cramer, 2001). 
Summary. Despite improvement from the original Chalfont scale, the NHS3 has been 
noted to have several limitations primarily in scoring and point assignment. The 1 to 4 
point rating scale for each item has been criticized as arbitrary and simplistic, thus 
exposing the scale to over and under-rating. The potential to report rare injuries and the 
same type of seizure more than once also contributes to overestimated scores. Further, in 
determining the overall impact of injury, the scale assigns points to only the most severe 
injury experienced by the patient without consideration for the frequency of injuries and 
falls (Cramer and French, 2001). The lack of evidence supporting the responsiveness of 
the scale is another crucial limitation of the NHS3 (Cramer, 2001). 
2.4.3 Liverpool Seizure Severity Scale (LSSS) 
The Liverpool Seizure Severity Scale (LSSS) was designed as a patient-reported scale 
with two subscales to summarize the severity of seizures from the perspective of the 
patient during AED treatment evaluation. In the original design, the first subscale 
“percept” contained 9 questions assessing the patients’ sense of control over seizures, 
while the second subscale “ictal” contained 10 questions assessing the severity of the 
ictal and post-ictal experience (Baker et al., 1991). The number of items in the LSSS has 
repeatedly changed over the course of several AED studies, and while the original scale 
used a 4-point Likert scale for each question, updated versions of the LSSS use a 5-point 
Likert scale to improve the sensitivity of the scale in detecting potential treatment effects 
of AEDs (Smith et al., 1995). The “percept” subscale was also eliminated from future 
versions of the LSSS (Cramer and French, 2001).  
Validity and Reliability. Assessment of early versions of the LSSS produced mixed 
results for both validity and reliability. Initial tests supported the validity and reliability of 
the “ictal” subscale (Baker et al., 1991, Wagner et al., 1995), but consistently suggested 
poor validity and reliability of the “percept” subscale (Baker et al., 1991, Wagner et al., 
1995, Rapp et al., 1998).  
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Subsequent modifications to improve the LSSS required patients with multiple seizure 
types to complete the questionnaire separately for their most severe seizures designated 
as “major”, and their least severe seizures designated as “minor”. Although modifications 
improved the test-retest and internal consistency reliability for both “ictal” and “percept” 
subscales, investigators recommended future testing of the validity and responsiveness of 
the scale (Baker et al., 1998b). 
Despite past revisions to the LSSS, Scott-Lennox et al. (2001) argued that the scale was 
unusable so they re-developed the scale to address limitations of complexity and length, 
the scale’s inability to account for the episodic nature of epilepsy, variation due to 
unclear definitions of “major” and “minor” seizures, and the ineffective “percept” 
subscale. After modifying the scale, investigators re-analyzed archival LSSS data from 
two studies evaluating Lamotrigine (LTG) therapy: Adjunctive Lamictal [Lamotrigine] in 
Epilepsy: Response to Treatment (ALERT) and a double-blind randomized control study 
(LAM30/31). The revised LSSS (LSSS 2.0) eliminated the “percept” subscale and 
generated a single “most severe” “ictal” score instead of the two “major” and “minor” 
seizure type ratings. Further adjustments enabled researchers to assign a value to 
previously “undefined” scores and reduce the amount of missing data for clinical research 
assessments. When the original LSSS scoring system was compared with the LSSS 2.0 in 
a test for reliability, the Cronbach’s alpha coefficient exceeded 0.7 for “major”, “minor”, 
and “most severe” data in the ALERT study as well as for “most severe” in the 
LAM30/31 study, thus supporting the internal consistency of the new scoring system. 
Construct validity was further confirmed by known-groups validity in data from both 
studies. The baseline scores for seizure types rated by physicians varied significantly (F = 
2.37 to F = 10.06, 2 d.f.) and patients with simple or generalized complex seizures scored 
high while patients with simple partial seizures scored lower, indicating that the LSSS 2.0 
is capable of differentiating patients with different types of seizures (Scott-Lennox et al., 
2001). 
Responsiveness. A randomized, placebo-controlled, double-blind, cross-over study 
involving 81 patients (33 males and 48 females) with a mean age of 34 years (range: 15 
to 67 years) found that following treatment with LTG, the “percept” subscale was 
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unresponsive to changes in severity (t = -0.28, CI: -1.0 to 0.43, p = 0.443) (Smith et al., 
1993), which was later confirmed by other studies (Smith et al., 1993, Wagner et al., 
1995, Rapp et al., 1998). Although the “ictal” subscale detected statistically significant 
difference in mean scores (t = -1.06, CI -1.90 to -0.22, p = 0.017) (Smith et al., 1993), it 
was not considered large enough to be clinically significant (Baker et al., 1998a). 
In the analysis of archival data measured at baseline and week 16 from the ALERT study 
(Scott-Lennox et al., 2001), the LSSS 2.0 appeared to be sensitive to changes in a 
patient’s condition of epilepsy following LTG therapy, which is known to be effective in 
reducing the frequency of seizures (Bryant-Comstock et al., 2001). Four physician-rated 
aspects of seizure severity (global rating of epilepsy status, overall severity of seizures, 
time to recovery, and severity of injuries) detected statistically significant change (p < 
0.05), which was reflected by a similar change in seizure severity as scored by the LSSS 
2.0 (Scott-Lennox et al., 2001). Additionally, the mean change (+/- SD) in LSSS 2.0 
scores for patients receiving LTG therapy at week 16 (9.2 ± 23.4, n = 467) was 
significantly higher (p = 0.0002) than the mean change in LSSS 2.0 scores for patients 
who had discontinued therapy before week 16 (0.8 ± 23.8, n = 87) and paralleled the 
significant improvement (p < 0.006) in other physician-rated aspects of seizure severity 
(Bryant-Comstock et al., 2001).  
Although it is unclear which version of the LSSS was employed by researchers in an 
assessment of the AED zonisamide, results of the 19 week study in 281 adults indicated 
statistically significant change between LSSS scores at baseline and week 19 (Dupont et 
al., 2010). However, clinical relevance was questioned due to small observed effects of 
the LSSS (Schmidt, 2010).  
Summary. Despite improvements to the scale (Scott-Lennox et al., 2001) and some 
evidence of responsiveness to change, further testing is required to verify the test-retest 
and inter-rater reliability specific to the revised scoring system. Evidence to support the 
clinical significance of change detected by the scale is also needed before 
recommendation as a reliable assessment tool in clinical trials (Schmidt, 2010). 
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2.4.4 Hague Seizure Severity Scale (HASS) 
The Hague Seizure Severity Scale (HASS) is an adaptation of the LSSS developed for 
use in the treatment of childhood epilepsy and measures the severity of seizures in 
children by parent report using self-administered questionnaires (Cramer, 2001). 
Containing 13 questions, the contents of HASS were suggested and modified by both 
parents and child neurologists (Carpay et al., 1996). 
Validity and Reliability. In a study of 80 children (46 males and 34 females) with a mean 
age of 9.6 years (range: 4 to 16 years) from outpatient child neurology departments and 
university hospitals in the Netherlands, HASS questionnaires were mailed to participants 
along with a follow-up questionnaire to 18 participants 2 weeks after completion of the 
first survey. Assessment of reliability indicated high internal consistency (Cronbach’s 
alpha of 0.85) and high test-retest reliability (Pearson correlation coefficient of 0.93), 
while the distribution of HASS scores supported the scale’s discriminant validity. HASS 
scores were also significantly correlated with the frequency of seizures (Spearman rank 
correlation coefficient of -0.33, p = 0.004) (Carpay et al., 1996). 
Reliability of the HASS is further supported by a 2-year prospective longitudinal study, 
assessing the changes in 28 children (14 males and 14 females) with a mean age of 6 
years (range: 7 months to 15 years) with medically intractable epilepsy who did not 
undergo surgical intervention. Kwan and Brodie (2000) define patients who continue to 
experience seizures as having intractable epilepsy. Children were recruited through the 
Dutch Collaborative Epilepsy Surgery Programme (DuCESP) and assessed in an 
outpatient clinic in the Netherlands. Across the 4 time points, children were relatively 
stable with no significant change in motor impairment, motor development, and 
perceived restrictions on social activity throughout the duration of the study. HASS 
scores also did not show statistically significant change of seizure severity from baseline 
(mean score range: 29-28) (van Empelen et al., 2007). 
In a study involving 117 children (67 males and 50 females) with a mean age of 9.7 years 
(range: 4 to 16 years) from outpatient child neurology departments in the Netherlands, 
investigators compared HASS scores with a neurologist completed Visual Analogue 
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Scale (VAS). Despite both scales showing large variability in severity scores within each 
seizure type, significant differences were found between three subgroups that sorted types 
of seizures by the degree of severity: minor (absences and simple partial seizures), 
intermediate (complex partial seizures), and major (generalized tonic-clonic seizures), 
thus supporting the construct validity. A statistically significant correlation (Pearson’s 
correlation coefficient of 0.45, p < 0.001) was also found between HASS and VAS 
scores. However, after stratifying for seizure type, correlations decreased (0.10 ≤ r ≤ 
0.26) and statistical significance was lost. A significant correlation found between HASS 
scores and seizure frequency (Pearson correlation coefficient of -0.28, p < 0.05) also 
decreased to r < 0.14 following stratification. Unlike HASS scores, VAS scores were not 
correlated with seizure frequency and were significantly correlated with the duration of 
epilepsy, schooling level, and mono- or poly-therapy. The substantial difference in 
ratings was not considered an indication of the validity of either rating scale but rather 
attributed to different factors impacting neurologists’ and parents’ perspectives (Carpay 
et al., 1997). 
Responsiveness. In a prospective longitudinal study on the consequences of 
hemispherectomy, HASS was used to measure the change in severity of seizures 
following surgery at an outpatient clinic in the Netherlands. For a period of two years, 12 
children (3 males and 9 females) with a mean age of 5.9 years (range: 0.3 to 11.1 years) 
at the time of surgery were evaluated once prior to hemispherectomy and three times after 
the procedure. Group mean scores assessed 6 months and 2 years after surgery showed 
significant decrease in severity from baseline with scores of 30.52 (SD 2.9, range 27 to 
39) for before surgery, 14.8 (SD 0.8, range 13 to 15, p < 0.01) for 6 months, and 13.25 
(SD 0.7, range 13 to 15, p < 0.01) at 2 years. Significant change was also detected by 
other measures of seizure frequency (Engel classification (Engel et al., 1993)), gross 
motor activity (Gross Motor Function Classification Scale), functional skills and 
caregiver assistance (Pediatric Evaluation of Disability Inventory), and perceived 
restrictions on social activity (Hague Restrictions in Childhood Epilepsy Scale) (van 
Empelen et al., 2004). Given that epilepsy surgery effectively reduces seizure activity in 
children with pharmacoresistant seizure disorders, the significant reduction in severity 
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detected by HASS is consistent with change in several other measures in the study and 
provides evidence to support its responsiveness (van Empelen et al., 2004).  
Significant change in HASS scores as well as frequency of seizures 3 months prior to 
treatment with methylphenidate and 1 month after treatment was also reported in a study 
testing the safety and efficacy of methylphenidate used to treat ADHD in 22 children 
(mean age: 11 years) with epilepsy (Santos et al., 2013). These findings provide further 
evidence to support the responsiveness of the scale. 
Summary. There is adequate evidence to support the effective measurement properties of 
the HASS for use as a parent-report measure in childhood epilepsy. Research on the 
clinical significance of change detected by the HASS would further strengthen its 
acceptance as a useful measure of seizure severity.  
2.4.5 Seizure Severity Questionnaire (SSQ) 
Acknowledging the limitations of previous seizure severity scales, the Seizure Severity 
Questionnaire (SSQ) was developed to assess treatment response in clinical trials 
(Cramer et al., 2002). As opposed to the LSSS 2.0 assessing the most severe seizure type 
currently experienced by the patient, the SSQ evaluates the most frequent seizure type 
and excludes questions that prevent the universal assessment of seizures, such as 
elements relating only to certain types of seizures and treatment effects. Other 
questionnaires, patient experience, and the expertise from epileptologists were consulted 
in the selection of content for the scale, as well as face and content validity (Cramer et al., 
2002).  
The initial structured interview completed in less than 35 to 50 minutes contained 22 
items that were categorized into warning, activity and recovery phases, along with 
questions on overall seizure severity and bothersomeness. The recovery phase was further 
divided into cognitive, emotional, and physical aspects of recovery. Items were scored by 
duration in minutes or by a 7-point Likert scale which were then combined into a total 
Summary Score (Cramer et al., 2002). 
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Following pilot testing of the initial SSQ, the questionnaire was revised to contain 24 
items (Borghs et al., 2014). Similar to the original questionnaire, items were divided into 
three categories of aura/warning, ictal, and postical events, as well as global questions 
assessing the overall seizure severity and bothersomeness. However, the phrasing of 
questions and response format were simplified to collect only “yes” or “no” answers and 
scores on the 7-point Likert scale. The revised SSQ also eliminated the final Summary 
Score, a question on the severity of the warning sign, and an item addressing nocturnal 
seizures (Cramer et al., 2002, Borghs et al., 2014). 
Validity and Reliability. In the pilot study, 91 adult patients (41 males and 50 females) 
with a mean age of 39 years (range: 17 to 77 years) were recruited from three centres in 
the United Kingdom and the United States. A total of 87 accompanying relatives or 
friends also provided information as observers to seizures. Patients and their observers 
were both interviewed by two interviewers independently and between 2 to 48 days 
following the first interview, 63 patients were re-interviewed. Results for the Summary 
Score showed moderate inter-rater (r = 0.76) and test-retest reliability (r = 0.74). 
However, the item-level assessment produced greater variability and reduced reliability 
for individual items. Items related to duration and the severity of cognitive effects, as 
well as procedural flaws were criticized for the poor reliability (Cramer et al., 2002).  
Comparing SSQ scores to other common scales revealed a low correlation with the VA 
scale (r = 0.24), and a moderate correlation with the NHS-3 (r = 0.31) and the LSSS (r = 
0.48). When compared with each other, the different constructs targeted by each scale 
were reflected in poor correlations between all scales (Cramer et al., 2002).  
A study in the United States collected data from 775 postal questionnaires to assess 
quality of life, and scores from the Centre for Epidemiologic Studies Depression Scale 
(CES-D), the SSQ, and the Sheehan Disability Scale (SDS). Results showed that 
individuals with severe, moderate and no symptoms of depression reported significantly 
different SSQ subscale scores (p < 0.0001 to p ≤ 0.05), and provided evidence that the 
SSQ was able to discriminate between different degrees of severity among respondents 
with and without depression (Cramer et al., 2003). 
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Despite the need for further scale development, the initial SSQ was described in several 
clinical research studies using the scale as an outcome assessment tool to demonstrate 
AED efficacy and correlation with other measures of quality of life (Cramer et al., 2003, 
Sancho et al., 2010, Schmidt, 2010, Cramer et al., 2012, Borghs et al., 2012). 
Although the revised SSQ was analyzed for sensitivity to change (Borghs et al., 2014), 
there are no published reports available that describe the specific validity and reliability 
of the newly revised scale. 
Responsiveness. In a review of measures evaluating the effect of AEDs on the post-ictal 
state (Schmidt, 2010), the initial SSQ detected changes in severity following treatment 
with the AED lacosamide in phase II/III clinical trials (Chung et al., 2007, Halász et al., 
2009). Data pooled from two randomized control trials with a total of 823 patients 
showed that patients allocated to the lacosamide treatment reported large mean 
improvements in severity detected by all subscales of the SSQ (Schmidt, 2010). Other 
studies assessing the long-term effects of lacosamide treatment using pooled data from 
three Phase III clinical trials reported statistically significant mean improvement of SSQ 
subscales after one year of lacosamide treatment (Cramer et al., 2012), as well as 
substantial reductions in seizure severity detected by the SSQ (Borghs et al., 2012). 
In a 6-month study involving 54 hospitals in Spain and 261 enrolled patients (122 males 
and 139 females) with a mean age of 40.8 years, the initial SSQ measured the mean 
change in seizure severity in regular clinical practice for patients with refractory partial 
epilepsy. Patients were also assessed using the Hamilton Anxiety Rating Scale (HAM-A), 
the Hamilton Depression Rating Scale (HAM-D), the Medical Outcomes Study—Sleep 
Scale (MOS-Sleep), the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), and the 
Morisky-Green test. When compared with baseline, both the 3 and 6 month change in 
SSQ scores were statistically significant (p < 0.0001). Although all of the rating scales 
showed a change in scores from baseline, changes detected by the SSQ were not directly 
compared with changes from the other rating scales (Sancho et al., 2010). 
To assess the revised SSQ, data from baseline to week 48 was pooled from two open-
label extensions of lacosamide clinical trials (n = 308 and n = 376). Patients were 
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grouped according to the type of seizure at baseline: complex partial seizures (CPS) or 
secondarily generalized partial seizures (SGPS), and individuals with ≥ 50% reduction in 
seizure frequency of the baseline seizure type were further classified as “responders”. For 
individuals with SGPS, the difference in mean change on the SSQ total score between 
responders and nonresponders was -0.94, while the difference for individuals with CPS 
was -0.47. The difference between SGPS- and CPS-specific scores (-0.47) indicated that 
patients with more severe seizures (SGPS) experienced a greater reduction in seizure 
frequency (Borghs et al., 2014). A study on the minimally important change thresholds 
for the SSQ determined that a 0.48-point change (range: 0.34 to 0.50) in the SSQ total 
score reflected clinically meaningful change (Cramer et al., 2014). Therefore, the results 
provided adequate evidence to support the responsiveness of the revised SSQ to change 
according to seizure type (Borghs et al., 2014). 
Summary. Although the revised version of the SSQ shows evidence to support its ability 
to detect clinically meaningful change, there is only some preliminary evidence of 
validity and reliability established for the original version of the SSQ. Prior to use of the 
SSQ as an endpoint in clinical trials of AEDs, further research was recommended (Nixon 
et al., 2013). 
2.5 Measure of Severity of Epilepsy Syndromes 
2.5.1 Epilepsy Syndrome Severity Scores- Child (ESSS-C) 
In contrast to measures evaluating the severity of seizures, the Epilepsy Syndrome 
Severity Scores-Child (ESSS-C) is a measure for the severity of epilepsy syndromes. The 
scale assigns a standard severity rating for each pediatric epilepsy syndrome to be used 
with other measures in evaluating the complete severity of seizure condition (Dunn et al., 
2004). 
The ESSS-C was developed with feedback from 18 pediatric neurologists to rate the 
severity of 36 pediatric epilepsy syndromes listed by the ILAE. Experts anonymously 
rated syndromes on a 10-point scale based on medical treatment response, seizure 
severity, and long-term prognosis in four rounds of testing. Final scores for each epilepsy 
syndrome were compiled into a single reference table (Dunn et al., 2004). During 
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development, syndromes with the highest and lowest ratings obtained unanimous or near 
unanimous ratings from neurologists. Although all scores were generally consistent, 
syndromes with middle range scores were more variably rated. Ratings were only 
unanimous for three syndromes: early myoclonic encephalopathy, early infantile epileptic 
encephalopathy with suppression burst, and simple febrile convulsion (Dunn et al., 2004).  
The difficulty in obtaining unanimous scores for all syndromes was partly attributed to 
the Delphi technique used to establish severity scores. Additionally, the rarity of certain 
syndromes, and individual variability in response to medical treatment, seizure severity, 
and long-term prognosis posed a barrier to obtaining consensus. Individual physician bias 
and differences in prioritization for different outcomes also influenced syndrome ratings. 
The developers state that obtaining additional information on the rationale behind 
experts’ scores would have provided further insight into the variability of certain 
syndrome scores. Other limitations to the ESSS-C concern future revisions to the ILAE 
classifications, as well as having only 12 of 18 enrolled experts complete the study (Dunn 
et al., 2004).  
To date, there have been no published studies testing the psychometric properties of the 
ESSS-C. 
2.6 Measure of Severity of Epilepsy 
2.6.1 Global Assessment of Severity of Epilepsy Scale (GASE)  
The Global Assessment of Severity of Epilepsy (GASE) Scale is a single-item measure 
developed by a panel of experts in pediatric neurology, epidemiology and 
neuropsychology to provide a more efficient measurement tool applicable to both clinical 
and research needs (Speechley et al., 2008). Designed as a clinician-report measure, the 
GASE Scale assesses the overall severity of a child’s epilepsy at the time of clinical 
assessment. The clinician is asked: “Taking into account all aspects of this patient’s 
epilepsy, how would you rate its severity at his/her last visit?”. It uses a 7-point Likert 
response scale with clinical descriptors ranging from “extremely severe”, to “not at all 
severe”. Ratings measure the overall severity of a patient’s epilepsy by considering all 
clinical aspects. Following assessment for clarity, relevance, usability, and face and 
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content validity, researchers conducted further testing for validity and reliability 
(Speechley et al., 2008). 
Validity and Reliability. Preliminary construct validation tested for convergent validity 
by comparing scores on the GASE Scale and seven clinical aspects of epilepsy identified 
by the experts as factors influencing the clinical assessment. The seven aspects are: 
frequency of seizures, intensity of seizures, falls or injuries during seizures, 
duration/severity of the post-ictal period, total dose/number of AEDs, side effects of 
AEDs, and interference of epilepsy or drugs with daily life activities. Each aspect was 
rated on a 7-point Likert scale where “1” represented “none, never, or mild” and “7” 
represented “extremely frequent, severe, or high” (Speechley et al., 2008). 
In the first test for validity, fifteen pediatric neurologists across Canada assessed between 
1 and 20 (mean: 9) of their patients on the GASE Scale and the seven clinical aspects. A 
total of 134 children with epilepsy and a mean age of 8.7 years (SD: 5.6 years) 
participated in the study. The Spearman rank-order correlation coefficients assessing the 
association between the GASE Scale scores and each of the seven clinical aspects were 
statistically significant (p = 0.001) and ranged from 0.49 to 0.87, with seizure frequency 
as the most strongly correlated aspect. Signifying the strength of the relationship, the 
seven clinical aspects together accounted for 80.9% of the variation in the GASE Scale 
with frequency of seizures accounting for the most variance in severity of epilepsy at 
77.5% (p < 0.001) (Speechley et al., 2008). 
When two pediatric neurologists independently rated 65 clinical case scenarios describing 
real patients with varying degrees of severity, age (mean: 7.3 years, range: 0 to 18 years), 
and sex (37 males and 28 females), neurologists fully agreed on the severity of 29 cases 
(45%) using the GASE Scale, but differed by one point for 27 cases (42%) and two 
points in 9 cases (13%). The weighted κ value of 0.85 (95% CI: 0.79 to 0.90) indicated 
“almost perfect agreement” and high inter-rater reliability (Speechley et al., 2008). 
High test-retest reliability was also found when two neurologists evaluated a random 
sample of 24 case scenarios from the initial 65 total cases after a 3-week interval. Perfect 
agreement was observed between times 1 and 2 in 13 cases (54%) for rater 1, and 15 
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cases (63%) in rater 2. However, a one-point difference in ratings was obtained in 10 
cases (42%) for rater 1 and 9 cases (37%) for rater 2. Rater 1 further experienced a two 
point difference in a single case (4%). The weighted κ value for agreement in rater 1 was 
0.90 (95% CI: 0.82 to 0.98) and 0.95 (95% CI: 0.91 to 0.98) for rater 2, while the 
Spearman rank correlation coefficient between times 1 and 2 was reported as 0.94 (95% 
CI: 0.89 to 0.96) (Speechley et al., 2008). 
The GASE Scale has also been tested for its validity in the adult population. After 
adapting the tool for use as a patient self-report measure, construct validity was assessed 
in 250 adult patients (mean age: 40.9, SD:14.9; 45.3% male) from the cross-sectional 
Neurological Disease and Depression Study (NEEDS) in Calgary, Canada. The seven 
response categories remained unchanged, while the phrasing of the question was adjusted 
for direct use by patients: “Taking into account all aspects of your epilepsy, how would 
you rate its severity now?”. Statistically significant (p < 0.05) Spearman’s rank 
correlations were reported between the GASE Scale ratings and clinical and self-reported 
outcomes of seizure frequency (r = -0.36), number of AEDs (r = -0.37), AED side effects 
(r = 0.35), and responses from the Patient Health Questionnaire (PHQ9) (r = 0.33), 
Hospital Anxiety and Depression Scale (HADS) (HADS Anxiety: -0.18; HADS 
Depression: -0.32), and the Global Assessment of Epilepsy Related Disability (GAERD) 
Scale (r = 0.57). The GAERD Scale was developed as a similar single-item 7-point Likert 
scale to evaluate the disability due to seizures in adult patients with epilepsy (Wiebe et 
al., 2013). Researchers noted that although it was statistically significant, GASE Scale 
ratings did not correlate strongly with type of seizure (r = 0.10). After adjusting for 
clinical and demographic characteristics using multiple linear regression, the strongest 
predictors of the severity of epilepsy were disability due to epilepsy and AED side 
effects. This study further supports the scale’s construct validity and value as an effective 
clinical assessment tool (Wiebe et al., 2013). 
Responsiveness. Responsiveness of the GASE Scale has not been assessed. A primary 
objective of the current study is to assess the responsiveness of the GASE Scale for 
clinical and research applications. 
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Summary. In addition to preliminary results supporting the construct validity and 
reliability of the GASE Scale, other key advantages include the 2 minute completion time 
and simple format. The scale also addresses the need for a global assessment of illness 
severity, which is important for decisions in therapy change, invasive treatments, and 
counselling, as well as assessing the impact of interventions. Further, the patient-specific 
rating enables cross-sectional comparison of patients and the assessment of the severity 
of epilepsy within patients over time (Speechley et al., 2008). 
Although preliminary evidence suggests the usefulness of the GASE Scale in evaluating 
the severity of epilepsy, the scale requires further testing of measurement properties. As 
noted by researchers, estimates may have been inflated due to the methodology of 
preliminary tests, and clinician ratings reflect only one of several relevant perspectives 
including parents and patients themselves. Therefore, the developers indicate that the 
next step is to compare GASE scores with more empirical and objective clinical patient 
data, along with other common measures of epilepsy-related clinical aspects in research 
studies and systematic tests of construct validity, reliability, and responsiveness to change 
in patients over time (Speechley et al., 2008).  
2.7 Summary of Measurement Scales 
Although there are various measurement tools available to assess epilepsy-related 
severity, each scale possesses limitations preventing its widespread use. Based on a 
review of common scales assessing the severity of seizures and epilepsy, suggestions 
were made to create a simple, broad and more flexible instrument that could incorporate 
all of the complex factors affecting the severity of epilepsy, including elements not 
assessed by current scales (Cramer, 2001). 
Table 2.1 provides an overview of the measurement properties for the existing severity 
scales described in this chapter. As reported by the ILAE, problems in the ease of use, 
sensitivity to changes, and subjectivity of assessments pose barriers toward the 
acceptance of a single standard epilepsy severity scale (Thurman et al., 2011). The 
majority of these scales have been shown in preliminary testing and some clinical trials to 
possess adequate face and content validity as well as sufficient reliability in inter-rater 
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and test-retest assessments (Cramer and French, 2001). However, none of the scales 
completely satisfy the psychometric requirements of outcome methods. Instrument flaws, 
complex scoring methods, and insufficient responsiveness testing are major concerns for 
the usefulness of these measures in assessing the severity of epilepsy and clinically 
relevant change (Cramer, 2001). Further, existing scales are often not practical for use in 
clinical or research settings due to the time commitment required to complete. Although 
only the HASS, ESSS-C, and GASE Scale were designed for the assessment of epilepsy 
in children (Baker et al., 1998a), measurement scales intended for adults may be adapted 
for use in children. 
The ILAE “Standards for Epidemiologic Studies and Surveillance of Epilepsy”, reports 
that standardized measures assessing the severity of seizures fail to measure the total 
impact of epilepsy (Thurman et al., 2011). The use of scales evaluating the severity of 
seizures as standard outcome measures in AED trials was also not recommended due to 
the lack of evidence for clinical utility (Mohanraj and Brodie, 2003). Since statistically 
significant change may not translate into change that is clinically meaningful to patients 
(Cramer et al., 2014), investigators must determine the amount of change on scales that is 
necessary to be considered useful to patients. Researchers propose that scales evaluate 
information from multiple sources to ensure all aspects of the patient’s epilepsy are 
examined (Cramer and French, 2001). A combination of several measures may also 
provide a more comprehensive evaluation of the multidimensional nature of epilepsy 
(Dunn et al., 2004, Wagner et al., 2009). 
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Table 2.1: Summary of the assessment of validity, reliability, and responsiveness for the severity scales reviewed in this chapter.  
A “+” indicates that there is evidence to support the psychometric property, while “-“ indicates that there is evidence that does not 
support it. Unclear or flawed results are designated by "?", while “0" indicates that no information was found. Where data are 
available for a scale that has undergone revisions, results reflect the assessment of the most recent version of the scale. Several 
investigators have indicated the lack of adequate testing for many of the measurement properties (Cramer, 2001, Cramer and French, 
2001, Mohanraj and Brodie, 2003, Nixon et al., 2013). Therefore, the evidence to support specific psychometric properties as 
indicated in this table may only represent partial supporting evidence. See Section 2.4 to 2.6 for details. The table design is adapted 
from Terwee et al. (2007). 
 
Content 
validity 
Internal 
consistency  
(α ≥ 0.7) 
Construct 
validity  
(κ ≥ 0.7 or as 
determined 
by 
investigators) 
Inter-rater 
reliability 
(ICC ≥ 0.7) 
Test-retest 
reliability 
(ICC/Pearson’s 
r ≥ 0.7) 
Responsiveness 
Clinical 
significance 
of detected 
change 
Seizure Severity Measures 
VA Scale + ? + + / ? 0 ? 0 
NHS3 + + + + / ? + / ? 0 0 
LSSS + + + + / ? + / ? + 0 
HASS + + + / ? 0 + + 0 
SSQ + 0 + / - / ? + / ? + / ? + + 
Syndrome Severity Measure 
ESSS-C + N/A 0 0 0 0 0 
Epilepsy Severity Measure 
GASE + N/A + + + TBD TBD 
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CHAPTER 3  
METHODS 
3.1 Assessing the Psychometric Properties of 
Measurement Scales 
Ensuring the quality of information collected by health measurement tools is essential to 
the appropriate design and selection of instruments used in both research and clinical 
assessment. Psychometric properties such as validity, reliability, and responsiveness 
provide insight into the accuracy and consistency of data collected by tools designed to 
measure subjective constructs such as quality of life, depression, or severity of illness. 
Validity refers to the degree to which an instrument measures what it was designed to 
measure, including subtypes of face, content, criterion, and construct validity. Reliability 
refers to the degree to which an instrument maintains the same results upon repeated 
application in similar conditions, including subtypes of test-retest, internal consistency, 
intra-rater, and inter-rater reliability (Streiner and Norman, 2008, pp.167-83, 247-74). 
Responsiveness refers to an instrument’s ability to detect change over time and is further 
divided into internal and external responsiveness (Husted et al., 2000).  
This study assesses the construct validity, stability, and responsiveness of the GASE 
Scale. The following subsections describe construct validity, stability, and responsiveness 
in further detail. 
3.1.1 Construct Validity 
Construct validity is the extent to which an instrument corresponds to a proposed 
interpretation of scores based on an underlying theory of the phenomenon under study 
(Aaronson et al., 2002, Porta, 2008). It is important because many attributes cannot be 
observed or measured directly, such as anxiety or pain. The measurement of these factors 
relies on hypothesized manifestations that can be observed, such as an increased heart 
rate in patients experiencing anxiety (Streiner and Norman, 2008, p.257). In the absence 
of a criterion measure for comparison, researchers assess construct validity. Hypothetical 
constructs are used to examine the logical relationships between measures and other 
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relevant variables, methods, and patterns of scores. Therefore, there are many different 
approaches in assessing the construct validity of an instrument depending on the study 
objectives and population and it is a continuous process of examination with no single 
best method (Aaronson et al., 2002). Common statistical methods include using group 
differences, correlation analyses, structural equation modelling, and factor analysis 
(Cronbach and Meehl, 1955, Smith, 2005). For example, the two forms of construct 
validation: convergent and divergent evaluate the correlation between measures and 
either related or unrelated variables, respectively (Streiner and Norman, 2008, pp.262-3). 
A challenge in construct validation arises in interpreting findings where the results of a 
measure may reveal similar scores for two groups that were expected to differ. Since 
construct validation assesses both the theory and the measure, Streiner and Norman 
(2008, pp.259) describe three possible explanations for such results: the instrument is 
effective, but the theory is incorrect; the theory is correct, but the instrument cannot 
discriminate between the two groups; or both the theory and the measure are defective. In 
such instances, further studies would be required to clarify the results. 
3.1.2 Stability 
Validation of measurement instruments also involves ensuring the reliability of test 
scores. Reliability refers to the amount of random and systematic error associated with a 
measurement. It reflects the degree to which an instrument maintains the same results 
upon repeated application with different examiners and at different times. One aspect of 
reliability is the stability of an instrument over time. Test-retest reliability often assesses 
stability of test scores from two different occasions when patients are unlikely to have 
changed. Generally, the time interval for observations is between 2 to 14 days (Streiner 
and Norman, 2008, pp.167-207). To quantify reliability, there are several forms of the 
reliability coefficient, namely the Pearson correlation, intra-class correlation (ICC), and 
kappa coefficient. Despite frequent use of kappa and the Pearson correlation, the ICC is 
considered superior and preferred for continuous scales (Guyatt et al., 2008, pp.257, 
Streiner and Norman, 2008, pp.183-8). Although there are no universally applicable 
conventions to interpret ICC values, a minimum test-retest coefficient of 0.7 is generally 
considered adequate for use in research (Guyatt et al., 2008, pp.257, Streiner and 
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Norman, 2008, pp.193-4). Streiner and Norman (2008, pp.182-3) describe three possible 
explanations for low coefficients of reliability: the scale is reliable, but the attribute itself 
has changed over time; the attribute did not change, but the scale is unreliable; or test 
scores recorded at the second occasion were influenced by the first administration of the 
test. 
It is important to establish stability of an instrument before testing for responsiveness to 
change, in order to increase confidence that changes detected are due to real change in the 
attribute being tested and not due to measurement error. 
3.1.3 Responsiveness 
Responsiveness is widely accepted as the ability of a measure to detect change (Aaronson 
et al., 2002). However, there is little agreement on the specific kind of change and no 
standard definition for responsiveness. Although the terms “responsiveness” and 
“sensitivity” are often used interchangeably, Liang (2000) argues that “sensitivity to 
change” is a broader term referring to any degree of change irrespective of clinical 
relevance or meaning to patients, while responsiveness is “the ability of an instrument to 
measure a meaningful or clinically important change in a clinical state” (Liang, 2000). 
While Streiner and Norman (2008, p.282) support the definition proposed by Liang, in a 
review listing sixteen variations of the definition for responsiveness, Beaton et al. (2001) 
recommended a simpler definition proposed by de Bruin et al. (1997): “Accurate 
detection of change when it has occurred”. Aaronson et al. (2002) suggest that 
“meaningful” change is a separate aspect of how data are interpreted. Despite 
disagreement over the concept and definition, as well as the interpretation and 
appropriate statistical methods used to assess responsiveness, researchers agree on the 
importance of establishing responsiveness for common measures used to detect change. 
Knowledge about the responsiveness of an instrument has value in both research and 
clinical practice where the accurate measurement of change in aspects of health status can 
be a primary outcome of clinical trials, influence treatment decisions, and help to monitor 
patients’ health over time. The selection of instruments, sample size estimation, and 
prioritization of outcomes also benefit from information on instrument responsiveness 
(Deyo et al., 1991). 
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As there is no consensus on the preferred statistical measure of responsiveness, 
investigators frequently report multiple statistics within a single study (Aaronson et al., 
2002, Streiner and Norman, 2008, p.283). Husted et al. (2000) note that the various 
statistical strategies assess either internal or external responsiveness. They define internal 
responsiveness as “the ability of a measure to change over a particular pre-specified time 
frame”, while external responsiveness is “the extent to which changes in a measure over a 
specified time frame relate to corresponding changes in a reference measure of health 
status” (Husted et al., 2000).  
Assessment of internal responsiveness involves distribution-based methods (Lydick and 
Epstein, 1993) where change is often detected in a measure in the context of pre-post 
clinical trials or treatments known to be efficacious. Common statistics include the paired 
t-test, Cohen’s effect size (ES), Guyatt’s Responsiveness Statistic (GRS), and the 
standardized response mean (SRM). Both Husted et al. (2000) and Zou (2005) favour the 
SRM as the most appropriate statistic, in part due to its independence from sample size 
and no need for an external criterion for change. Assessment of external responsiveness 
involves anchor-based methods (Lydick and Epstein, 1993) where changes are often 
compared with a criterion measure or other related constructs. Common methods include 
the receiver operating characteristic (ROC) curve, correlation analyses, and regression 
models. These statistical approaches and their respective limitations are discussed in 
greater detail by Deyo et al. (1991), Stratford et al. (1996), Husted et al. (2000), Liang 
(2000), Beaton et al. (2001), Stratford and Riddle (2005), Zou (2005), Norman (2008), 
and Streiner and Norman (2008, pp.282-95).  
The interpretation of responsiveness statistics is also complicated by disagreement over 
the magnitude of change considered important. The Minimally Important Difference, 
Cohen’s thresholds for the SRM, probability of change statistic, and the reliable change 
index are some ways in which researchers calculate whether documented change is 
adequate. Understanding this change is further complicated by potential biases related to 
“response shift” and “implicit theories of change” (Streiner and Norman, 2008, p.279). 
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3.2 Data Source and Study Population 
The data for this thesis are from the Health-Related Quality of Life in Children with 
Epilepsy Study (HERQULES). HERQULES was a two-year prospective cohort study 
that primarily assessed the health-related quality of life (HRQL) and risk factors in 
children with new onset epilepsy in Canada (Speechley et al., 2012). Using a two-stage 
clustered sampling strategy between April 2004 and April 2007, 53 (74%) out of a total 
of 72 practicing paediatric neurologists listed under the Canadian Association of Child 
Neurology (CACN) recruited the parents of children with epilepsy (median: 9 families 
per physician) meeting the inclusion criteria of the study. The study sample included new 
cases of epilepsy in children (range: 4 to 12 years old) with ≥ 2 unprovoked seizures. The 
children had not received past confirmation of the diagnosis and were seeing a paediatric 
neurologist for the first time. Participating parents possessed sufficient English language 
skills and were the primary caregivers of the children for a minimum of 6 months. 
Patients were excluded from the study if they were diagnosed with other progressive or 
degenerative neurological disorders and other co-morbid non-neurological disorders 
presumed to have an impact on quality of life (Speechley et al., 2012). 
At four designated time points (baseline, 6, 12, and 24 months following the diagnosis of 
epilepsy), a mailed parent-report questionnaire collected information on HRQL and a 
series of child and family characteristics, while a clinician-report form collected 
information on clinical characteristics of the child’s epilepsy. Of a total of 456 parents 
mailed questionnaires, 374 (82%) completed the baseline questionnaire and 283 parents 
(62%) returned all 4 completed questionnaires. Compared with those who completed the 
study (n = 283), children who were lost to follow-up (n = 91) were not significantly 
different (p > 0.05) in mean age, sex, severity of epilepsy, behavior problems or levels of 
health-related quality of life. Older parents who were married, had more education, and a 
higher income were more likely to complete and return all questionnaires, however 
(Speechley et al., 2012). The baseline time point was defined as the closest time to 
diagnosis following recruitment of parents into the study and it was intended to record the 
immediate impact of diagnosis on HRQL and associated factors. Together, the specific 
time intervals were selected to avoid missing potential fluctuations in scores while 
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ensuring enough time to detect changes in the measures and with minimal burden on 
participants. Further details of the HERCULES study methodology and results are 
described by Speechley et al. (2012).  
3.3 Measurement 
3.3.1 Parent Questionnaire 
In the HERQULES study, the mailed parent questionnaire documented parents’ 
perceptions of HRQL in children with epilepsy in the first two years following diagnosis 
as well as several family characteristics. HRQL was measured using the Quality of Life 
in Childhood Epilepsy Questionnaire (QOLCE) and the Child Health Questionnaire 
(CHQ) (Speechley et al., 2012). 
In the current study, two questions from the CHQ (Fig. 3.1) and QOLCE (Fig. 3.2) 
sections are used to evaluate the responsiveness of the GASE Scale scores and to assess 
the association between the parents’ perception of current child health and the child’s 
severity of epilepsy as evaluated by the GASE Scale.  
 
Figure 3.1: HERQULES study CHQ question 8.12 assessing the parents’ perception 
of change in child health. 
 
Figure 3.2: HERQULES study QOLCE question 1.15 assessing the parents’ 
perception of current child health. 
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3.3.2 Physician Report Form 
In the HERQULES study, the physician form collected information on the clinical 
characteristics of the child’s epilepsy. The two-page clinician-report form documented 
the patient’s date of birth, last visit to the neurologist, age of first seizure, family history 
of epilepsy, whether the patient was attending school, type of seizure(s), epilepsy 
syndrome, CSE, exclusive nocturnal seizures, epilepsy medication information, major co-
morbid conditions such as behavioural, cognitive, and motor problems, as well as 
neurological deficits, and the severity of epilepsy. The type of seizure was classified 
according to the ILAE’s 1981 classification of seizures (ICES), while the type of epilepsy 
and epilepsy syndrome were classified according to the ILAE’s 1989 classification of 
epilepsies and epileptic syndromes (ICE) (Speechley et al., 2003). In particular, the 
overall severity of epilepsy was measured using the GASE Scale and specific information 
was collected on seven core clinical aspects of epilepsy (Speechley et al., 2008).  
Several questions on the physician form were adapted from the Canadian Epilepsy Data 
Registry (CEDAR Visit Form), and the physician form used to test both the Quality of 
Life in Epilepsy for Adolescents questionnaire (QOLIE-AD-48) and the Impact of Child 
Neurologic Handicap Scale (ICNH) (Speechley et al., 2003).  
Appendix A contains the physician form used at baseline and Appendix B contains the 
physician form used at follow-up (6, 12, and 24 months). 
In the current study, scores from the GASE Scale are compared with data gathered from 
other questions in the physician form to evaluate the construct validity, stability, and 
responsiveness of the GASE Scale. 
3.3.2.1 The GASE Scale 
The GASE Scale is a global rating scale assessing the overall individual severity of 
childhood epilepsy at time of clinical assessment. It consists of a single-item, 7-point 
Likert scale with the clinical descriptors: “not at all severe”, “a little severe”, “somewhat 
severe”, “moderately severe”, “quite severe”, “very severe”, and “extremely severe” (Fig. 
3.3). By considering all clinical aspects, clinicians are asked to assess the overall severity 
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of a child’s epilepsy (Speechley et al., 2008). A detailed description of the development 
and results of previous validity and reliability testing is provided in Chapter 2 section 
2.6.1.  
 
Figure 3.3: The Global Assessment of Severity of Epilepsy (GASE) Scale: a single-
item, 7-point global rating scale assessing the overall severity of epilepsy in children. 
3.3.2.2 Clinical Aspects of Epilepsy 
Seven core clinical aspects of epilepsy were included in the physician form to document 
the frequency of seizures, intensity of seizures, falls or injuries during seizures, severity 
of the post-ictal period (conceptually defined as the abnormal condition immediately after 
an epileptic seizure and return to baseline (Fisher and Engel, 2010)), amount of AEDs, 
side effects of AEDs, and the interference of epilepsy or drugs with daily activities. These 
aspects were rated on a 7-point Likert scale with descriptors for 1 representing “none or 
never” and 7 representing “extremely frequent, severe or high”. The seven aspects were 
selected by an expert panel of three paediatric neurologists and two experienced epilepsy 
research coordinators. The expert panel had independently reviewed and agreed to these 
clinical aspects of a patient’s epilepsy as key contributing factors in the clinical 
assessment of the severity of epilepsy (Speechley et al., 2008). 
3.3.2.3 Other Clinical Characteristics of Epilepsy 
In addition to the seven core clinical aspects of epilepsy, the current study also evaluates 
information on the reporting of convulsive status epilepticus (CSE), exclusive nocturnal 
seizures, and the total number of AEDs (recorded as a numerical quantity, in contrast to 
the Likert scale response described above for “amount of AEDs”).   
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3.4 Data Analysis 
All statistical analyses were conducted using Statistical Analysis System (SAS) software 
Version 9.3 (SAS Institute Inc., Cary, NC, US). 
3.4.1 Construct Validity of the GASE Scale 
Objective 1: Hypotheses and Procedure 
To evaluate the construct validity of the GASE Scale, a priori hypotheses were created to 
predict the correlations between GASE scores and neurologists’ ratings of clinical 
characteristics of epilepsy contributing to the overall diagnosis of severity. Data recorded 
at Times 1, 2, 3, and 4 (baseline, 6, 12, and 24 months post-diagnosis, respectively) were 
analyzed at each time point. In this study, the clinical descriptors of the GASE Scale were 
specified using numerical values (1 to 7), with “not at all severe” designated as “1” and 
“extremely severe” designated as “7”.  
a) GASE scores will be correlated with several clinical aspects of epilepsy rated 
by neurologists. These correlations are predicted to be at least moderate (r ≥ 0.3). 
In the first test of construct validity, each of 7 clinical aspects of epilepsy (frequency of 
seizures, intensity of seizures, falls or injuries during seizures, severity of post-ictal 
period, amount of AEDs, side effects of AEDs, and interference of epilepsy or drugs with 
daily activities) was predicted to independently correlate at least moderately (≥ 0.3) with 
GASE scores. Of these 7 clinical aspects, the frequency of seizures was further predicted 
to possess the strongest correlation with GASE scores. Correlations between GASE 
scores and each clinical aspect of epilepsy were tested using Spearman rank-order 
correlation, 95% confidence intervals (CI) and a P-value < 0.05 for statistical 
significance. Correlations were interpreted using Cohen’s classification for effect size. A 
correlation of 0.10 to 0.30 was regarded as weak; 0.30 to 0.50 was regarded as moderate; 
and > 0.50 was regarded as strong (Cohen, 1988, pp.79-80). Multiple linear regression 
was additionally used to assess the specific relationship between GASE scores and the 7 
core clinical aspects of epilepsy, while adjusting for the effects of the other aspects. The 
coefficient of determination (R
2
) and the associated 95% CI was used to assess the 
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proportion (%) of total variation in GASE scores explained by the 7 clinical aspects of 
epilepsy.  
b) GASE scores will be correlated at least moderately (r ≥ 0.3) with the “total 
number of AEDs” reported by neurologists. 
In the second test of construct validity, the total number of AEDs was predicted to 
correlate at least moderately (≥ 0.3) with GASE Scale scores. Spearman rank-order 
correlation, 95% CI and a P-value < 0.05 for statistical significance was calculated and 
also interpreted using Cohen’s criteria for effect size (Cohen, 1988, pp.79-80). 
c) and d) GASE scores will indicate more severe epilepsy for children who have 
experienced CSE than those who have not and GASE scores will indicate less severe 
epilepsy for children whose seizures are exclusively nocturnal. 
In the third and fourth tests of construct validity, children who had experienced CSE were 
predicted to have higher GASE scores than children who had not, while children with 
exclusively nocturnal seizures were predicted to have lower GASE scores than children 
with daytime seizures. For both tests, independent-samples t-tests compared mean GASE 
scores for patients with and without these specific epilepsy conditions. 
e) GASE scores will be correlated with parents’ perception of child health. The 
correlation will be at least moderate (r ≥ 0.3) with GASE scores indicating more 
severe epilepsy associated with parents reporting children’s health as poorer. 
In the fifth and final test of construct validity in this study, neurologists’ ratings using 
GASE were predicted to correlate at least moderately (≥ 0.3) with parents’ perception of 
child health as rated by the QOLCE question (Figure 3.2) asking parents: “Compared to 
other children his/her age, how do you think your child’s health has been in the past 4 
weeks? Please consider your child’s epilepsy as part of his/her health when you answer 
this question.” Responses to this QOLCE question are assigned a numerical value from 1 
to 5, with “1” designated as “Poor” and “5” designated as “Excellent”. Spearman rank-
order correlation, 95% CI and a P-value < 0.05 for statistical significance were calculated 
and interpreted using Cohen’s criteria for effect size (Cohen, 1988, pp.79-80). 
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3.4.2 Stability of the GASE Scale 
Objective 2: Hypothesis and Procedure 
Since there is no gold standard for the assessment of overall severity of epilepsy, seven 
key clinical aspects of epilepsy were determined to be the most objective clinical 
indicators of stable severity of epilepsy as recorded in the Physician Form based on 
physician’s most recent interviews with patients and parents. The following seven 
external criteria were used to compare with the GASE Scale to assess stability and 
change over time: frequency of seizures, intensity of seizures, falls or injuries during 
seizures, severity of the post-ictal period, CSE, exclusive nocturnal seizures, and number 
of AEDS currently. The selection of these clinical aspects was informed by a paediatric 
neurologist and epileptologist. To ensure a sufficiently short time frame where patients’ 
status was less likely to have changed (Streiner and Norman, 2008, pp.182), the 6 month 
time interval from Time 2 (6 months post-diagnosis) to Time 3 (12 months post-
diagnosis) was chosen for this analysis. At Time 2, about 6 months had elapsed since 
diagnosis, allowing time for more stable diagnoses and for patients to adjust to treatment. 
a) In patients for whom neurologists’ reports of key clinical aspects of epilepsy 
and a composite score indicate stability in the patient’s epilepsy over a period of 6 
months, GASE scores will remain stable over the same time period. 
For each clinical aspect and the composite score combining all aspects, the patient sample 
was divided into two sub-groups: “stable” and “changed”. Patients were classified as 
“stable” if ratings for the clinical criteria showed zero change from Time 2 to Time 3. 
Stability for the clinical aspect of CSE was further restricted to patients who had not 
experienced the condition at either time point. Patients were classified as “changed” if 
ratings for the clinical criteria were different at Time 2 and Time 3.  
For each “stable” sub-sample, the distribution, intra-class correlation coefficient (ICC) 
and its 95% CI, and paired t-test were calculated for GASE scores from Time 2 to Time 
3.  
The distribution of raw change scores for each “stable” sub-sample was calculated by 
subtracting Time 3 scores from Time 2 scores. The detailed point change and direction of 
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change (positive or negative) were assessed. A positive change score indicated an 
increase in severity of epilepsy as rated by the GASE Scale.  
The ICC estimate quantifies the reliability of measurements over time (Shrout and Fleiss, 
1979). It can be defined as the proportion of total variability explained by the variability 
among patients (Deyo et al., 1991). In addition to the strength of the correlation between 
GASE scores at Time 2 to Time 3, it also assesses variation of the slope and intercept. 
The approach calculating ICC from an analysis of variance described by Deyo et al. 
(1991, pp. 149-50) was used for this analysis, with 95% CI obtained on the basis of F-
distribution. 
The ICC ranges between 0 to +1, with 1 indicating perfect reliability and 0 suggesting 
poor reliability (Deyo et al., 1991). Although there are no universally applicable 
conventions to interpret ICC values, a general rule is that ICC should exceed 0.7 for 
adequate reliability (Guyatt et al., 2008, pp.257, Streiner and Norman, 2008, pp.193-4). 
The paired t-test was additionally used to test whether mean GASE scores for the stable 
sub-group at Time 2 were statistically different at Time 3 at the 5% significance level. 
b) In patients whose parents’ reports of child health status indicate stability in 
the patient’s epilepsy over a period of 6 months, GASE scores will remain stable 
over the same time period. 
Following the same method used for the clinical criteria, the patient sample was divided 
into two sub-groups according to the parents’ reports of child health, as rated by the 
QOLCE question (Figure 3.2) asking parents: “Compared to other children his/her age, 
how do you think your child’s health has been in the past 4 weeks? Please consider your 
child’s epilepsy as part of his/her health when you answer this question.” Patients were 
classified as “stable” if their parents’ ratings showed zero change from Time 2 to Time 3. 
The remaining patients were classified as “changed’ for having different scores at the two 
time points. In the “stable” sub-sample, the ICC of the GASE scores, and the 95% CI 
were calculated for Time 2 to Time 3. The paired t-test was additionally used to test 
whether GASE scores for the stable sub-group were statistically different (p > 0.05) at the 
two time points. 
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3.4.3 Responsiveness of the GASE Scale 
Objective 3: Hypotheses and Procedure  
Since there is no consensus on the best statistical measure of responsiveness, multiple 
statistics (distribution-based and anchor-based methods) were adopted to assess the 
responsiveness of the GASE Scale.  
Distribution-based methods (internal responsiveness): 
a) The GASE Scale will be able to detect statistically significant changes in the 
severity of epilepsy over time (from baseline to 6, 12, and 24 months post-diagnosis). 
In the assessment of internal responsiveness, the GASE Scale was predicted to detect 
statistically and clinically relevant changes in the severity of epilepsy over the course of 
the study. Data from Time 1 (baseline) was used as a reference to compare with data 
from Times 2, 3, and 4 (6, 12, and 24 months post-diagnosis, respectively). 
Responsiveness detected by the GASE Scale over the 4 time points was tested using the 
standardized response mean (SRM). The SRM evaluates the magnitude of change over 
time and is accepted as the most appropriate statistic for assessing internal responsiveness 
when a gold standard is not available (Zou, 2005). At each time point compared to 
baseline, the mean change in GASE score was divided by the standard deviation of the 
respective change in scores. The standard deviation reflects the variability of the change 
scores, with lower variability relative to mean change resulting in a larger SRM 
coefficient (Husted et al., 2000). To interpret the SRM, the probability of change statistic 
(p) was also calculated based on the cumulative normal distribution. The probability of 
change ranges between 0.5, indicating no ability to detect change, and 1.0 indicating 
perfect ability (Zou, 2005). A probability of greater than 0.5 would suggest that the scale 
is able to detect changes thereby providing evidence to support the utility of the GASE 
Scale in detecting changes in the severity of epilepsy in children.
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Anchor-based methods (external responsiveness): 
b) Change in severity of epilepsy reported using the GASE Scale over a period 
of 12 months will be correlated with neurologists’ reports of changes in key clinical 
aspects of epilepsy and a composite score of the aspects over the same time period.  
The seven key clinical aspects of epilepsy and their composite score that were described 
previously to assess the stability of the GASE Scale in Objective 2 were used in this 
analysis: frequency of seizures, intensity of seizures, falls or injuries during seizures, 
severity of the post-ictal period, CSE, exclusive nocturnal seizures, and number of AEDS 
currently. For the GASE Scale and each of the clinical aspects of epilepsy, change scores 
were calculated by taking the difference between Time 1 and Time 3 data, where change 
was most likely to occur for patients in the study. Correlations between change scores for 
the GASE Scale and for each of the clinical aspects or the composite score were then 
determined using Spearman rank-order correlation (without assuming normality of the 
data), 95% CI, and a P-value < 0.05 for statistical significance. As with the test of 
construct validity, correlations were interpreted using Cohen’s classifications for effect 
size (Cohen, 1988, pp.79-80). 
c) Change in severity reported using the GASE Scale over a period of 12 
months will be correlated with changes in parents’ perceptions of child health status 
over the same time period. 
Since parents are the observers most familiar with their child’s epilepsy, this test of 
responsiveness used the parents’ perception of change in child health as an external 
reference measure of health status. Two questions from the Parent Questionnaire 
provided information on the parents’ perception of change and it was predicted that these 
opinions would correlate with changes reported using GASE scores. CHQ Question 8.12 
(Figure 3.1) asked parents: “Compared to one year ago, how would you rate your child’s 
health now?”. Responses were assigned a numerical value from 1 to 5, with “1” 
designated as “Much better now than 1 year ago” and “5” designated as “Much worse 
now than 1 year ago”. QOLCE Question 1.15 (Figure 3.2) asked parents: “Compared to 
51 
 
 
 
other children his/her age, how do you think your child’s health has been in the past 4 
weeks? Please consider your child’s epilepsy as part of his/her health when you answer 
this question.” Responses were assigned numerical values from 1 to 5, with “1” 
representing “Poor” and “5” representing “Excellent”. For analysis of the QOLCE 
question, change scores were calculated from the difference of scores between Time 1 
and Time 3. For the CHQ question only Time 3 data were used since the question 
specifies a comparison point of one year ago. Correlations between GASE change scores 
and parents’ perception of change were determined using Spearman rank-order 
correlation, 95% CI, and a P-value < 0.05 for statistical significance. Cohen’s 
classifications for effect size were also used to interpret correlations (Cohen, 1988, pp.79-
80). 
d) In patients for whom neurologists’ reports of key clinical aspects of epilepsy 
and the composite score indicate change in the patient’s epilepsy over a period of 12 
months, common responsiveness statistics will show that GASE scores also change 
over the same time period. 
The seven key clinical aspects of epilepsy from the Physician Form and their composite 
score that were previously used to assess the stability of the GASE Scale in Objective 2 
were used to assess change in the patient’s epilepsy over a period of 12 months: 
frequency of seizures, intensity of seizures, falls or injuries during seizures, severity of 
the post-ictal period, CSE, exclusive nocturnal seizures, and number of AEDS currently.  
As conducted in the assessment of stability, for each of the seven clinical indicators or the 
composite score combining all aspects, the patient sample was divided into two sub-
groups: “stable” and “changed”. Patients were classified as “stable” if ratings for the 
clinical criteria showed zero change from Time 1 to Time 3. The remaining patients were 
classified as “changed” for ratings that were different at Time 1 and Time 3.  
For each “changed” sub-sample, Cohen’s Effect Size (ES), Guyatt’s Responsiveness 
Statistic (GRS), and a paired t-test were calculated to compare GASE scores at Time 1 
with Time 3. The Area under the Receiver Operating Characteristic Curve (AUROC) and 
95% CI were additionally assessed to determine the probability of GASE change scores 
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to differentiate and agree with the “stable” and “changed” classifications determined by 
the clinical criteria. 
The ES quantifies the magnitude of difference in mean scores by dividing the difference 
between mean scores at Time 1 to Time 3 with the standard deviation of baseline scores, 
thereby transforming the score change into a standard measure of change. This is 
expressed mathematically as: (M1 – M3) / SDBaseline, where M1 represents the mean of 
scores from Time 1; M3 represents the mean of scores from Time 3; and SDBaseline is the 
standard deviation of the scores from Time 1. Related to ES, GRS divides the mean 
change in scores from Time 1 to Time 3 by the standard deviation of the change for the 
stable patients. This is expressed mathematically as: (M1 – M3) / SDStable, where M1 
represents the mean of scores from Time 1; M3 represents the mean of scores from Time 
3; and SDStable is the standard deviation of the change in stable patients. As suggested by 
Guyatt, the GRS expresses responsiveness as a function of the variability in score 
changes for stable patients, instead of the standard deviation of baseline scores (Deyo et 
al., 1991). ES and GRS were interpreted using Cohen’s conventions for ES: 0.2 was 
regarded as small; 0.5 was regarded as moderate; and 0.8 was regarded as large (Streiner 
and Norman, 2008, pp. 153).  
By comparing the mean GASE scores at Time 1 with Time 3 for each “changed” sub-
sample, the paired t-test was additionally used to test whether Time 1 GASE scores were 
significantly different at Time 3 at the 5% significance level.  
The ROC is commonly used to evaluate the discriminative accuracy of measurement 
scales and can be interpreted as an estimate of the probability of concordance (SAS 
Institute Inc., 2006). Using the sensitivity (true positive rate) and specificity (false 
positive rate) of score changes, the AUROC assesses the probability of the measurement 
scale to correctly classify patients as “stable” or “changed” (Deyo et al., 1991). In the 
context of this study, the seven clinical aspects and composite score acted as the external 
reference for true stability and change. Therefore, the AUROC analysis assessed whether 
the GASE Scale identified patients as “stable” (no change in GASE score from Time 1 to 
Time 3) or “changed” (any change in GASE score from Time 1 to Time 3) in accordance 
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with classifications determined by the clinical aspects or composite score. To interpret 
this probability, an AUROC of 0.50 to 0.70 was classified as low; 0.70 to 0.90 was 
classified as moderate; and greater than 0.90 was classified high (Streiner and Norman, 
2008, pp. 161).  
e) In patients whose parents’ reports of child health indicate change in the 
patient’s epilepsy over a period of 12 months, common responsiveness statistics will 
show that GASE scores also change over the same time period. 
As with the previous assessments involving parents’ perception of child health, two 
questions from the Parent Questionnaire provided information on the parents’ perception 
of change. CHQ Question 8.12 (Figure 3.1) asked parents: “Compared to one year ago, 
how would you rate your child’s health now?” Responses were assigned a numerical 
value from 1 to 5, with the following designations: 1 = “Much better now than 1 year 
ago”; 2 = “Somewhat better now than 1 year ago”; 3 = “About the same now as 1 year 
ago”; 4 = “Somewhat worse now than 1 year ago”; and 5 = “Much worse now than 1 year 
ago”. QOLCE Question 1.15 (Figure 3.2) asked parents: “Compared to other children 
his/her age, how do you think your child’s health has been in the past 4 weeks? Please 
consider your child’s epilepsy as part of his/her health when you answer this question.” 
Responses were assigned numerical values from 1 to 5, with the following designations: 
1 = “Excellent”; 2 = “Very good”; 3 = “Good”; 4 = “Fair” and 5 = “Poor”. For analysis of 
the QOLCE question, change scores were calculated from the difference of scores 
between Time 1 and Time 3. For the CHQ question only Time 3 data were used since the 
question specifies a comparison point of one year ago.  
For both questions from the Parent Questionnaire, the patient sample was divided into 
two sub-groups: “stable” and “changed”. Patients were classified as “stable” if ratings for 
the QOLCE question showed zero change from Time 1 to Time 3, while a rating of 3 
(“About the same now as 1 year ago”) on the CHQ question classified patients as 
“stable”. The remaining patients not classified as “stable” were classified as “changed”.  
For each “changed” sub-sample, ES, GRS, and a paired t-test were calculated to compare 
GASE scores at Time 1 with Time 3. AUROC and the 95% CI were additionally 
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measured to determine the probability of GASE change scores to discriminate and agree 
with the “stable” and “changed” classifications determined by the perception of parents. 
 ES and GRS were interpreted using Cohen’s conventions for ES: 0.2 was regarded as 
small; 0.5 was regarded as moderate; and 0.8 was regarded as large (Streiner and 
Norman, 2008, pp. 153). To interpret the AUROC, 0.50 to 0.70 was classified as low; 
0.70 to 0.90 was classified as moderate; and greater than 0.90 was classified high 
(Streiner and Norman, 2008, pp. 161).  
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CHAPTER 4  
RESULTS 
4.1 Sample Characteristics 
Table 4.1 shows the characteristics of the sample. Of a total of 456 parent questionnaires 
mailed in HERQULES, 374 (82%) were completed and returned at Time 1 (baseline), 
335 (73%) returned at Time 2 (6 months post-diagnosis), 304 (67%) returned at Time 3 
(12 months post-diagnosis) and 282 (62%) returned the final questionnaire at Time 4 (24 
months post-diagnosis). At Time 1, the mean age of children was 7.5 (SD: 2.3) years and 
52% were male, while parents had a mean age of 37.7 (SD: 6.1%) years and only 7.2% 
were male. The majority of parents were married (79.6%), biological parents (94.1%) and 
working full or part-time (67%). Just over one half (53.4%) of parents had completed 
college or university and approximately 45% of parents had an annual household income 
of $70,000 or more. At Time 4, the majority of parents who were retained throughout the 
duration of the study were married (82.5%), working full or part-time (76.9%), had 
completed college or university (63.3%), and had an annual household income of 
$70,000 or more (54%).  
Table 4.2 and Figure 4.1 show the descriptive statistics for GASE scores reported by 
neurologists at all four time points. At Time 1, the mean GASE score was 2.57 (SD: 
1.19), indicating somewhere between “a little severe” and “somewhat severe” on the 
GASE Scale. By Time 4, the mean GASE score had decreased to 1.7 (SD: 1.06), 
indicating somewhere between “not at all severe” and “a little severe”.  
4.2 Results 
4.2.1 Construct Validity of the GASE Scale 
Objective 1: Results 
a) GASE scores will be correlated with several clinical aspects of epilepsy rated 
by neurologists. These correlations are predicted to be at least moderate (r ≥ 0.3). 
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The strength of the association between the physician-rated GASE scores and the seven 
clinical aspects of epilepsy was estimated by the Spearman correlation coefficient and is 
summarized in Table 4.3. All correlations were statistically significant at p = 0.001, 
except at Time 1 for the side effects of AEDs (p = 0.0128) and the amount of AEDs (p = 
0.20). In most cases, the seven clinical aspects were moderately correlated with the 
GASE Scale. Over time, there was a general increase in the size of the correlations 
between each clinical aspect and GASE scores. At every time point, three clinical aspects 
were consistently correlated the highest with the GASE Scale: frequency of seizures, 
intensity of seizures, and interference of epilepsy or drugs with daily activities. Although 
intensity of seizures showed the strongest correlation with GASE scores at Time 1, 
frequency of seizures demonstrated the strongest correlation with GASE scores at Time 
2. The frequency of seizures was also strongly correlated with GASE scores at Times 3 
and 4 along with the interference of epilepsy or drugs with daily activities. In the multiple 
linear regression analysis adjusting for the effects of the other clinical variables, the seven 
clinical aspects gradually accounted for more variation in GASE scores over time (from 
28% at Time 1 to 70% at Time 4) (Tables 4.4a-d). The intensity of seizures explained the 
most variation in GASE scores at Time 1. However, at Times 2, 3, and 4, the frequency 
of seizures and interference of epilepsy or drugs with daily activities accounted for the 
most variance when all clinical aspects were included in the model. The following 
paragraphs describe the results of this analysis in further detail (Table 4.3). 
At Time 1, GASE scores demonstrated a moderate correlation with the following clinical 
aspects of epilepsy: interference of epilepsy or drugs with daily activities, intensity of 
seizures, frequency of seizures, and falls or injuries during seizures, with correlations 
ranging from 0.34 to 0.30. A weak correlation was observed with the severity of the post-
ictal period, side effects of AEDs, and the amount of AEDs, with correlations between 
0.14 and 0.07, with the correlation for amount of AEDs not being statistically significant. 
Time 1 results indicate that higher severity of epilepsy was correlated with more frequent, 
severe or high interference of epilepsy or drugs with daily activities, intensity and 
frequency of seizures, and falls or injuries during seizures. Higher severity of epilepsy 
was only weakly correlated with more frequent, severe or high severity of the post-ictal 
period and side effects of AEDs.  
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At Time 2, GASE scores demonstrated at least moderate correlations with four of the 
seven clinical aspects of epilepsy: frequency of seizures, interference of epilepsy or drugs 
with daily activities, intensity of seizures, and side effects of AEDs, with correlations 
ranging from 0.51 to 0.30. The frequency of seizures additionally showed a strong 
correlation with GASE scores (r = 0.51; 95%CI: 0.42 to 0.58; p < 0.001). A weak 
correlation was observed between GASE scores and falls or injuries during seizures, 
amount of AEDs, and the severity of the post-ictal period, with correlations ranging 
between 0.28 and 0.24. Time 2 results indicate that those with epilepsy of higher severity 
had higher frequency of seizures, interference of epilepsy or drugs with daily activities, 
intensity of seizures, and side effects of AEDs. Additionally, these patients only had a 
weak association with higher falls or injuries during seizures, amount of AEDs, and the 
severity of the post-ictal period. 
At Time 3, GASE scores demonstrated at least a moderate correlation with five of the 
seven clinical aspects of epilepsy: frequency of seizures, interference of epilepsy or drugs 
with daily activities, intensity of seizures, side effects of AEDs, and falls or injuries 
during seizures, with correlations ranging from 0.49 to 0.31. A weak correlation was 
observed between GASE scores and severity of the post-ictal period, and the amount of 
AEDs, with correlations of 0.24 and 0.23. Time 3 results indicate that those with epilepsy 
of higher severity had higher frequency of seizures, interference of epilepsy or drugs with 
daily activities, intensity of seizures, side effects of AEDs, and falls or injuries during 
seizures. These patients were only weakly associated with higher severity of the post-ictal 
period and the amount of AEDs. 
At Time 4, all seven clinical aspects were at least moderately correlated with GASE 
scores, with correlations ranging from 0.60 to 0.37. The frequency of seizures, 
interference of epilepsy or drugs with daily activities, and the intensity of seizures 
demonstrated a strong correlation, while a moderate correlation was observed with the 
side effects of AEDs, falls or injuries during seizures, amount of AEDs, and severity of 
the post-ictal period. Time 4 results indicate that those with epilepsy of higher severity 
had more severe states of all seven clinical aspects. 
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The multiple linear regression analysis adjusted for the effects of the seven core clinical 
aspects of epilepsy and is summarized in Tables 4.4a-d. At Time 1, the seven core 
clinical aspects together accounted for R
2 
= 28% (95% CI: 19% to 35%; p < 0.001) of the 
total variation in GASE scores, with intensity of seizures having the strongest 
independent effect in the physician-rated severity of epilepsy relative to the other factors 
in the model (Regression coefficient: 0.24; p < 0.001). At Time 2, the seven clinical 
aspects together accounted for R
2 
= 43% (95% CI: 32% to 50%; p < 0.001) of the total 
variation, with frequency of seizures having the strongest independent effect relative to 
the other aspects in the model (Regression coefficient: 0.28; p < 0.001). Similarly at Time 
3, the clinical aspects together accounted for R
2 
= 44% (95% CI: 34% to 51%; p < 0.001) 
of the total variation, with frequency of seizures having the strongest independent effect 
relative to the other factors in the model (Regression coefficient: 0.35; p < 0.001). By 
Time 4, the seven clinical aspects accounted for R
2 
= 70% (95% CI: 63% to 75%; p < 
0.001) of the total variation in GASE scores, with frequency of seizures again having the 
strongest independent effect relative to the other six clinical aspects (Regression 
coefficient: 0.47; p < 0.001). 
b) GASE scores will be correlated at least moderately (r ≥ 0.3) with the “total 
number of AEDs” reported by neurologists. 
Table 4.5 shows the correlation between GASE scores and the total number of AEDs at 
all four time points. At Time 1, more severe GASE scores were only weakly correlated 
with a higher total number of AEDs (r = 0.18; 95% CI: 0.08 to 0.28; p < 0.001). 
However, at Times 2 (r = 0.32; 95% CI: 0.22 to 0.41; p < 0.001), 3 (r = 0.36; 95% CI: 
0.26 to 0.45; p < 0.001) and 4 (r = 0.37; 95% CI: 0.27 to 0.46; p < 0.001), GASE scores 
indicating higher severity were moderately correlated with a higher total number of 
AEDs. 
c) GASE scores will indicate more severe epilepsy for children who have 
experienced CSE than for those who have not. 
Results of the subgroup analysis for CSE are presented in Table 4.6. At all four time 
points, there was no significant difference in mean GASE scores between patients with 
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and without CSE occurrence since the previous visit (p > 0.05). This indicates that the 
overall severity of epilepsy as rated by the GASE Scale did not differ between patients 
with or without CSE at baseline, 6, 12, and 24 months post-diagnosis. 
d) GASE scores will indicate less severe epilepsy for children whose seizures are 
exclusively nocturnal. 
Results of the subgroup analysis for exclusive nocturnal seizures are presented in Table 
4.7. At Times 1, 2, and 4, the independent-samples t-test found a significant difference (p 
< 0.05) in mean GASE scores between patients with exclusive nocturnal seizures and 
those whose seizures were not exclusively nocturnal, but the mean scores were not 
significantly different at Time 3. This indicates that the overall severity of epilepsy as 
rated by the GASE Scale was higher for patients whose seizures were not exclusively 
nocturnal at three of the four times assessed. 
e) GASE scores will be correlated with parents’ perception of child health. The 
correlation will be at least moderate (r ≥ 0.3) with GASE scores indicating more 
severe epilepsy associated with parents reporting children’s health as poorer. 
Parents’ perception of child health was rated by the QOLCE question asking parents: 
“Compared to other children his/her age, how do you think your child’s health has been 
in the past 4 weeks? Please consider your child’s epilepsy as part of his/her health when 
you answer this question.” The strength of the association between the physician-rated 
GASE scores and the parents’ perception of child health was estimated by the Spearman 
correlation coefficient and is presented in Table 4.8. GASE scores showed a weak 
correlation with parents’ perception of child health at Times 1 (r = -0.17; 95% CI: -0.27 
to -0.07; p = 0.0013) and 2 (r = -0.23; 95% CI: -0.33 to -0.12; p < 0.001), indicating that 
more severe GASE scores were only weakly associated with the parents’ perception of 
poorer child health at baseline and 6 months post-diagnosis. However, a consistent 
increase in the strength of the association resulted in moderate correlations at Times 3 (r 
= -0.31; 95% CI: -0.41 to -0.20; p < 0.001) and 4 (r = -0.34; 95% CI: -0.45 to -0.23; p < 
0.001), indicating that GASE scores indicative of more severe epilepsy were moderately 
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associated with the parents’ perception of poorer child health at 12 and 24 months post-
diagnosis.  
4.2.2 Stability of the GASE Scale 
Objective 2: Results 
a) In patients for whom neurologists’ reports of key clinical aspects of epilepsy 
and a composite score indicate stability in the patient’s epilepsy over a period of 6 
months, GASE scores will remain stable over the same time period. 
Overall distribution of GASE change scores from Time 2 to Time 3 
As summarized in Table 4.9a, a total of 311 children had GASE severity ratings for Time 
2 and Time 3. The mean change was -0.14 (95% CI -0.26 to -0.03) with change ranging 
from -4 points to +4 points on the GASE Scale. Of the 311 children, 157 (50.5%) showed 
identical GASE scores at the two time points, indicating no change in severity. While 62 
(20%) children experienced an increase in GASE scores (1-point increase: 46, 2-point 
increase: 14, 3-point increase: 1, and 4-point increase: 1 individual), 92 (29. 5%) children 
experienced a decrease in GASE scores (1-point decrease: 66, 2-point decrease: 20, 3-
point decrease: 5, and 4-point decrease: 1 individual). 
Distribution of GASE change scores from Time 2 to Time 3 in sub-samples of patients 
with no change in the clinical aspects of epilepsy and composite score 
As summarized in Table 4.9b and c, the results indicate that for all “stable” sub-samples, 
the majority of patients (48.8% to 73.3%) did not change in the severity of epilepsy as 
rated by the GASE Scale. The highest percentage of patients not showing a change in 
GASE scores was for the composite score: of the 101 patients showing stability on all 
seven clinical aspects taken together, 74 (73.3%) did not experience change in GASE 
scores. As predicted, GASE scores were generally stable in patients for whom 
neurologists reported stability in the key clinical aspects of epilepsy and the composite 
score. Although GASE change scores varied as much as a ±4-point change from Time 2 
to Time 3, the change values were centred around zero change with only a small number 
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of patients with larger change scores.  
For patients classified as stable on the basis of each of the clinical aspects individually, 
there were more children with decreasing severity of epilepsy over time rather than 
increasing, indicating that while physicians’ rating of the individual clinical aspects 
themselves did not change, they tended to record more improvement than deterioration in 
the overall severity of epilepsy. Detailed descriptions of the distribution (Table 4.9b) and 
direction (Table 4.9c) of GASE scores for each “stable” sub-sample are provided below. 
Frequency of seizures 
Of the 321 patients with ratings for the frequency of seizures at Time 2 and Time 3, 176 
(58%) showed no change in frequency of seizures. Of these children, two thirds showed 
no change in the severity of epilepsy as rated by the GASE Scale, while one quarter 
showed a 1-point change and the remaining small proportion showed a 2 or 3-point 
change. In terms of the direction of GASE change, about 13% experienced an increase in 
severity, with the vast majority experiencing only a 1-point increase, and 21% 
experienced a decrease in severity, again with most experiencing only a 1-point decrease.  
Intensity of seizures 
Of the 319 patients with ratings for the intensity of seizures at Time 2 and Time 3, 170 
(53%) showed no change in intensity of seizures. Of these children, two thirds showed no 
change in the severity of epilepsy as rated by the GASE Scale, while one quarter showed 
a 1-point change and the remaining small proportion showed a 2, 3, or 4-point change. In 
terms of the direction of GASE change, approximately 17% experienced an increase in 
severity, with the majority experiencing only a 1-point increase, and 19% experienced a 
decrease in severity, again with most experiencing only a 1-point decrease. 
Falls or injuries during seizures 
Of the 321 patients with ratings for falls or injuries during seizures at Time 2 and Time 3, 
252 (78.5%) showed no change in falls or injuries during seizures. Over one half of these 
children showed no change in severity of epilepsy as rated by the GASE Scale, while one 
third showed a 1-point change and the remaining small proportion showed a 2, 3, or 4-
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point change. In terms of the direction of GASE change, about 19% experienced an 
increase in severity, with the vast majority experiencing only a 1-point increase, and 26% 
experienced a decrease in severity, again with most experiencing only a 1-point decrease. 
Severity of the post-ictal period 
Of the 321 patients with ratings for the severity of the post-ictal period at Time 2 and 
Time 3, 203 (63.2%) showed no change in the severity of the post-ictal period. Over one 
half of these children showed no change in severity of epilepsy as rated by the GASE 
Scale, while about one third showed a 1-point change and the remaining proportion 
showed a 2, 3, or 4-point change. In terms of the direction of GASE change, 
approximately 16% experienced an increase in severity, with the majority experiencing a 
1-point increase, and 25% experienced a decrease in severity, again with most 
experiencing only a 1-point decrease. 
CSE 
Of the 322 patients with ratings for CSE at Time 2 and Time 3, 295 (91.6%) did not have 
CSE at both time points. Approximately one half of these children showed no change in 
severity of epilepsy as rated by the GASE Scale, while over one third showed a 1-point 
change and the remaining proportion showed a 2, 3, or 4-point change. In terms of the 
direction of GASE change, 21% experienced an increase in severity, with the vast 
majority experiencing a 1-point increase, and 30% experienced a decrease in severity, 
again with most experiencing only a 1-point decrease. 
Exclusive Nocturnal Seizures 
Of the 319 patients with ratings for exclusive nocturnal seizures at Time 2 and Time 3, 
292 (91.5%) showed no change in exclusive nocturnal seizures. One half of these 
children showed no change in severity of epilepsy as rated by the GASE Scale, while just 
over one third showed a 1-point change and the remaining small proportion showed a 2, 
3, or 4-point change. In terms of the direction of GASE change, about 20% experienced 
an increase in severity, with the majority experiencing a 1-point increase, and 30% 
experienced a decrease in severity, again with most experiencing only a 1-point decrease. 
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Number of AEDs currently 
Of the 318 patients with ratings for number of AEDs currently at Time 2 and Time 3, 268 
(84.3%) showed no change in the number of AEDs currently. Just over one half of these 
children showed no change in severity of epilepsy as rated by the GASE Scale, while 
over one third showed a 1-point change and the remaining proportion showed a 2, 3, or 4-
point change. In terms of the direction of GASE change, 19% experienced an increase in 
severity, with most experiencing a 1-point increase, and 29% experienced a decrease in 
severity, again with the majority experiencing a 1-point decrease. 
Composite score 
Of the 310 patients with ratings for all seven clinical aspects of the composite score at 
Time 2 and Time 3, 101 (32.6%) showed no change in any of the aspects. Of these 
children, three quarters showed no change in severity of epilepsy as rated by the GASE 
Scale, while one fifth showed a 1-point change and the remaining small proportion 
showed a 2 or 3-point change. In terms of the direction of GASE change, about 16% 
experienced an increase in severity, with the majority experiencing a 1-point increase, 
and 11% experienced a decrease in severity, again with most experiencing a 1-point 
decrease. 
Stability statistics: ICC, 95% CI, and paired t-test comparing GASE scores from Time 2 
with Time 3.  
Results summarized in Table 4.9d show the stability statistics for GASE scores in the 
“stable” sub-samples of patients, classified using the individual clinical aspects of 
epilepsy and the composite score. For each classification, the ICC was greater than 0.50 
and ranged between 0.52 and 0.64. Overall severity of epilepsy as rated by the GASE 
Scale was most stable when correlated with frequency of seizures (ICC 0.64; 95% CI 
0.54 to 0.72) and the least stable when correlated with CSE (ICC 0.52; 95% CI 0.43 to 
0.59). This indicates that relative to the other clinical aspects, the frequency of seizures 
appears to be most strongly related to a physician’s overall assessment of stability in the 
severity of epilepsy using the GASE Scale. Results of the paired t-test show that only 
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intensity of seizures, falls or injuries during seizures, and the composite score did not 
have statistically different GASE scores at Times 2 and 3 (p > 0.05), suggesting that other 
factors in addition to the selected clinical criteria may influence the assessment of 
stability in the severity of epilepsy. 
b) In patients whose parents’ reports of child health status indicate stability in 
the patient’s epilepsy over a period of 6 months, GASE scores will remain stable 
over the same time period. 
Results are shown in Table 4.10. In the “stable” sub-sample according to the parents’ 
perception of child health in the past 4 weeks, the ICC for GASE scores from Time 2 to 
Time 3 was 0.53 (95% CI 0.38 to 0.65) with t = 1.7 and p > 0.05. GASE scores at the two 
time points did not differ significantly, providing some evidence that GASE scores 
remained stable over the 6 month period. 
4.2.3 Responsiveness of the GASE Scale 
Objective 3: Results 
The overall distribution of GASE change scores from Time 1 to Time 3 is summarized in 
Table 4.11. A total of 331 children in the patient sample had GASE severity ratings for 
Time 1 and Time 3. The mean change was -0.73 (95% CI -0.86 to -0.59) with change 
ranging from -5 points to +3 points on the GASE Scale. Of the 331 children, just over 
one third showed identical GASE scores at the two time points, indicating no change in 
severity. While 13% of children experienced an increase in GASE scores, just over one 
half experienced a decrease in GASE scores. 
Distribution-based methods (internal responsiveness): 
a) The GASE Scale will be able to detect statistically significant changes in the 
severity of epilepsy over time (from baseline to 6, 12, and 24 months post-diagnosis). 
The SRM and probability of change statistic (p) for the GASE Scale at Time 1 (baseline) 
compared with Time 2, 3, and 4 (6, 12, and 24 months post-diagnosis) are summarized in 
Table 4.12. According to Cohen’s benchmarks for effect size (Cohen, 1988, p.40), the 
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SRMs comparing mean change in GASE scores from baseline to 6 months (SRM:-0.49, 
95% CI -0.61 to -0.37), 12 months (SRM: -0.58, 95% CI -0.71 to -0.45), and 24 months 
post-diagnosis (SRM: -0.68, 95% CI -0.81 to -0.55) showed a moderate magnitude of 
change. The corresponding probability of change was significantly greater than 0.5 for all 
three comparisons with baseline: 6 months (p: 0.69; 95% CI 0.65 to 0.73), 12 months (p: 
0.72; 95% CI 0.68 to 0.76), and 24 months post-diagnosis (p: 0.75; 95% CI 0.71 to 0.79), 
indicating that the GASE Scale has a greater than 50% probability of detecting change. 
This suggests that the GASE Scale is sensitive in detecting change in the severity of 
epilepsy in children.  
Anchor-based methods (external responsiveness): 
b) Change in severity of epilepsy reported using the GASE Scale over a period 
of 12 months will be correlated with neurologists’ reports of changes in key clinical 
aspects of epilepsy and a composite score of the aspects over the same time period.  
As shown in Table 4.13, the mean change in GASE scores from Time 1 to Time 3 
demonstrated a moderate correlation with changes in: the composite score, intensity of 
seizures, frequency of seizures, and severity of the post-ictal period, with correlations 
ranging from 0.47 to 0.33. Increases in the severity of GASE scores from Time 1 to Time 
3 were moderately correlated with increases in the composite score, intensity and 
frequency of seizures, and severity of the post-ictal period over the same time period.  
A weak correlation was observed with changes in falls or injuries during seizures (r = 
0.22; 95% CI 0.11 to 0.32; p < 0.001), indicating that increases in the severity of GASE 
scores from Time 1 to Time 3 were only weakly associated with increases in falls or 
injuries during seizures.  
The mean change in GASE scores also demonstrated a weak correlation with: the number 
of AEDs currently, CSE, and exclusive nocturnal seizures, with correlations ranging from 
0.10 to -0.01 and these correlations were not statistically significant.  
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c) Change in severity reported using the GASE Scale over a period of 12 
months will be correlated with changes in parents’ perceptions of child health status 
over the same time period. 
The mean change in GASE scores from Time 1 to Time 3 demonstrated a weak 
correlation with change in parents’ perception of their child’s health. As shown in Table 
4.14, the change in parents’ perception of child health as measured using the QOLCE 
question: “Compared to other children his/her age, how do you think your child’s health 
has been in the past 4 weeks? Please consider your child’s epilepsy as part of his/her 
health when you answer this question.” showed a weak correlation with change in mean 
GASE scores (r = -0.12; 95% CI -0.23 to 0; p = 0.053). An increase in severity detected 
by the physician-rated GASE Scale from Time 1 to Time 3 was only weakly correlated 
with the parents’ perception of a decline in their child’s health during the same time 
period. 
The change in parents’ perception of their child’s health as measured by the CHQ 
question asking parents: “Compared to one year ago, how would you rate your child’s 
health now?” at Time 3, was also weakly correlated with the mean change in GASE 
scores from Time 1 to Time 3 (r = 0.24; 95% CI 0.12 to 0.35; p < 0.001). An increase in 
severity detected by the GASE Scale was only weakly correlated with the parents’ 
perception of their child’s worsening health status. 
d) In patients for whom neurologists’ reports of key clinical aspects of epilepsy 
and the composite score indicate change in the patient’s epilepsy over a period of 12 
months, common responsiveness statistics will show that GASE scores also change 
over the same time period.  
For all “changed” sub-samples (clinical aspects and the composite score), GASE scores 
from Time 1 to Time 3 demonstrated a moderate to large ES and GRS, ranging from 0.56 
to 0.84. This suggests that when change is detected in specific clinical criteria, the GASE 
Scale is responsive to this change. Results are summarized in Table 4.15. The largest ES 
of 0.77 was found for the change in GASE scores of patients classified as “changed” in 
the severity of the post-ictal period. However, the largest GRS of 0.84 was found for 
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GASE change scores of patients from the “changed” sub-samples for both frequency and 
intensity of seizures. The results indicate that the GASE Scale detected at least a 
moderate magnitude of change from Time 1 to Time 3 when clinical criteria recorded 
change in frequency of seizures, intensity of seizures, falls or injuries during seizures, 
severity of the post-ictal period, CSE, exclusive nocturnal seizures, and number of AEDS 
currently.  
The paired t-test comparing the mean GASE scores at Time 1 with Time 3 showed that 
for all “changed” sub-samples except for CSE, there was a statistically significant 
difference (p < 0.001) in GASE scores at the two time points. The results indicate that the 
GASE Scale was responsive to changes in the clinical aspects. The smaller t-statistic for 
GASE scores in the “changed” CSE sub-sample suggests that other factors may have a 
greater influence on the assessment of change in the severity of epilepsy using the GASE 
Scale. CSE does not appear to be a key factor in this assessment. The magnitude and 
significance of the t-statistic in all sub-samples of “changed” patients (except CSE) were 
also larger than for patients classified as “stable” in the tests for stability, providing 
further evidence that GASE scores detected greater change in the Time 1 to Time 3 
“changed” sub-samples than the Time 2 to Time 3 “stable” sub-samples. 
For all clinical aspects and the composite score, the AUROC consistently demonstrated a 
low area under the curve and ranged from 0.50 to 0.67. Probability of concordance was 
highest for patients classified by frequency of seizures with an AUROC of 0.67 (95% CI 
0.61 to 0.74), followed by the intensity of seizures (0.63; 95% CI 0.56 to 0.69) and 
severity of the post-ictal period (0.59; 95% CI 0.53 to 0.65). The results indicate some 
ability of the GASE Scale to discriminate “stable” and “changed” patients according to 
select clinical criteria or the composite score. 
e) In patients whose parents’ reports of child health indicate change in the 
patient’s epilepsy over a period of 12 months, common responsiveness statistics will 
show that GASE scores also change over the same time period. 
For the sub-sample classified as “changed” by the parents’ perception of child health, 
GASE scores from Time 1 to Time 3 demonstrated a moderate to large ES and GRS, 
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ranging from 0.61 to 0.70. Results are summarized in Table 4.16. The results indicate that 
the GASE Scale detected at least a moderate magnitude of change from Time 1 to Time 3 
when parents reported a change in their child’s health. This suggests that when change is 
perceived by parents, the GASE Scale is responsive to this change. 
The paired t-test comparing the mean GASE scores at Time 1 with Time 3 showed that in 
the “changed” sub-samples for the parents’ perception of child health, there was a 
statistically significant difference (p < 0.001) in GASE scores at the two time points. 
These results indicate that the GASE Scale detected changes in overall severity of 
epilepsy that were also perceived and reported by parents as changes in child health. 
Parents’ perception of their child’s health may also be a factor that was considered by 
physicians to assess change in the overall severity of epilepsy using the GASE Scale. The 
magnitude and significance of the t-statistic in the sub-sample of “changed” patients (t = 
7.48; p < 0.001) was also larger than for patients classified as “stable” (t = 1.7; p = 0.09) 
in the tests for stability, providing further evidence that GASE scores detected greater 
change in the Time 1 to Time 3 “changed” sub-sample than the Time 2 to Time 3 
“stable” sub-sample.  
For GASE scores in the “changed” sub-sample of the parents’ perception of child health, 
the discriminative accuracy was low, with an AUROC of 0.50 (95% CI 0.44 to 0.57) and 
0.54 (95% CI 0.47 to 0.61). These results indicate low ability of the GASE Scale to 
discriminate “stable” and “changed” patients according to the parents’ perception of 
stability and change in their child’s health status. 
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Table 4.1: Demographic characteristics of children and parents at Times 1 
(baseline), 2 (6 months post-diagnosis), 3 (12 months post-diagnosis), and 4 (24 
months post-diagnosis). 
 TIME 1: 
N = 373 
TIME 2: 
N = 335 
TIME 3: 
N = 304 
TIME 4:  
N = 282 
CHILDREN 
Age, years (mean (SD)) 7.5 (2.3) 7.9 (2.4) 8.5 (2.3) 9.5 (2.3) 
Sex, % Male 52.3 51.3 50.3 51.4 
PARENTS 
Age, years (mean (SD)) 37.7 (6.1) 38.2 (5.8) 39.1 (5.9) 40.3 (5.6) 
Sex, % Male 7.2 5.1 5.3 7.1 
Relationship with child, % 
Biological parent 94.1 94.9 94.4 95.7 
Other (step; foster; adoptive; 
guardian) 
5.9 5.1 5.6 4.3 
Work status, % 
Working full or part-time 67.0 70.6 73.5 76.9 
Full time homemaker 21.6 19.4 18.9 15.5 
Not working (due to child’s 
health; for ‘other’ reasons) 
7.6 5.8 4.6 4.3 
Other (looking for work out the 
home; student) 
3.8 4.2 3.0 3.3 
Highest level of education, % 
< 8 years 1.9 0.6 0.3 0.4 
8-12 years 9.4 8.3 6.3 5.3 
Completed high school 22.3 21.7 19.8 19.6 
Completed vocational/technical 
training 
13.1 11.0 13.9 11.4 
Completed college/university 44.5 49.8 50.8 51.6 
Completed graduate school 8.9 8.6 8.9 11.7 
Marital status, % 
Married 79.6 79.6 80.3 82.5 
Never married 9.4 8.7 7.9 6.1 
Separated or divorced 9.4 10.8 10.5 10.7 
Other (widowed; remarried) 1.6 0.9 1.3 0.7 
Annual household income, % 
< $40,000 21.7 22.4 19.5 14.8 
$40,000 to $69,999 30.9 27.4 23.6 26.9 
$70,000 to $99,999 22.6 23.1 26.4 23.6 
≥ $100,000 22.3 24.9 27.1 30.3 
Unknown 2.5 2.2 3.4 4.4 
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Table 4.2: GASE Scale scores at Times 1 (baseline), 2 (6 months post-diagnosis), 3 (12 
months post-diagnosis), and 4 (24 months post-diagnosis). 
Time N Missing Mean (SD) Median 
Time 1 376 11 2.57 (1.19) 2 
Time 2 343 44 1.97 (1.12) 2 
Time 3 340 47 1.86 (1.04) 2 
Time 4 322 65 1.70 (1.06) 1 
 
 
 
Figure 4.1: Distribution of GASE Scale scores at Times 1 (baseline), 2 (6 months post-
diagnosis), 3 (12 months post-diagnosis), and 4 (24 months post-diagnosis). 
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Table 4.3: Results for Objective 1a.  Spearman rank correlations of GASE scores compared 
with seven clinical aspects of epilepsy assessed by neurologists at Times 1 (baseline), 2 (6 
months post-diagnosis), 3 (12 months post-diagnosis), and 4 (24 months post-diagnosis).   
  Clinical aspects of epilepsy 
 
 
Frequency 
of seizures 
Intensity of 
seizures 
Side 
effects of 
AEDs 
Interference 
of epilepsy 
or drugs 
with daily 
activities 
Falls or 
injuries 
during 
seizures 
Severity of 
the post-
ictal period 
Amount of 
AEDs 
Time 
1 
Spearman 
Rho 
0.30 0.33 0.13 0.34 0.30 0.14 0.07 
95% CI 0.21, 0.39 0.23, 0.42 0.03, 0.23 0.25, 0.43 0.20, 0.39 0.04, 0.24 -0.04, 0.17 
P-value < 0.0001 < 0.0001 0.0128 < 0.0001 < 0.0001 0.007 0.20 
Time 
2 
Spearman 
Rho 
0.51 0.45 0.30 0.47 0.28 0.24 0.28 
95% CI 0.42, 0.58 0.36, 0.53 0.20, 0.40 0.39, 0.55 0.18, 0.38 0.14, 0.34 0.17, 0.37 
P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Time 
3 
Spearman 
Rho 
0.49 0.48 0.38 0.49 0.31 0.24 0.23 
95% CI 0.40, 0.57 0.36, 0.53 0.29, 0.47 0.41, 0.57 0.21, 0.40 0.14, 0.34 0.13, 0.33 
P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Time  
4 
Spearman 
Rho 
0.60 0.58 0.46 0.60 0.42 0.37 0.38 
95% CI 0.53, 0.67 0.50, 0.64 0.37, 0.54 0.52, 0.66 0.32, 0.50 0.27, 0.46 0.28,0.47 
P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
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Table 4.4a: Results for Objective 1a.  Multiple-linear regression analysis showing the 
coefficient of determination for each model (R
2
) and regression coefficients of the cross-
sectional association between GASE scores and seven clinical aspects of epilepsy at Time 1 
(baseline). 
 Regression coefficients 
 Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Intercept 1.85* 1.14* 1.05* 1.09* 0.89* 0.86* 0.90* 
Frequency of 
seizures 
0.22* 0.17* 0.17* 0.16* 0.16* 0.17* 0.10* 
Intensity of 
seizures 
Not 
included 
0.32* 0.26* 0.29* 0.28* 0.26* 0.24* 
Falls or 
injuries 
during 
seizures 
Not 
included 
Not 
included 
0.16* 0.17* 0.15* 0.18* 0.15* 
Severity of 
the post-ictal 
period 
Not 
included 
Not 
included 
Not 
included 
-0.05 -0.04 -0.05 -0.07 
Amount of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.15 -0.04 -0.09 
Side effects 
of AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.22* 0.17* 
Interference 
of epilepsy or 
drugs with 
daily 
activities 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.23* 
R
2
 0.09** 0.19** 0.21** 0.20** 0.21** 0.24** 0.28** 
Adjusted R
2
 0.09** 0.19** 0.20** 0.19** 0.20** 0.23** 0.27** 
95% CI for 
R
2 
0.03, 
0.14 
0.11, 
0.25 
0.13, 
0.27 
0.12, 
0.26 
0.13, 
0.27 
0.15, 
0.31 
0.19, 
0.35 
n 372 371 370 367 365 352 345 
Missing 15 16 17 20 22 35 42 
 
* Statistically significant at p < 0.05. ** Statistically significant at p < 0.0001. 
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Table 4.4b: Results for Objective 1a.  Multiple-linear regression analysis showing the 
coefficient of determination for each model (R
2
) and regression coefficients of the cross-
sectional association between GASE scores and seven clinical aspects of epilepsy at Time 2 
(6 months post-diagnosis). 
 Regression coefficients 
 Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Intercept 1.07* 0.87* 0.79* 0.81* 0.44* 0.39* 0.42* 
Frequency of 
seizures 
0.49* 0.39* 0.39* 0.38* 0.34* 0.34* 0.28* 
Intensity of 
seizures 
Not 
included 
0.22* 0.16* 0.18* 0.15 0.15 0.17* 
Falls or 
injuries 
during 
seizures 
Not 
included 
Not 
included 
0.14 0.14 0.13 0.11 0.07 
Severity of 
the post-ictal 
period 
Not 
included 
Not 
included 
Not 
included 
-0.02 -0.03 -0.07 -0.10 
Amount of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.28* 0.18* 0.13* 
Side effects of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.18* 0.10 
Interference 
of epilepsy or 
drugs with 
daily 
activities 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.24* 
R
2
 0.31** 0.34** 0.34** 0.34** 0.38** 0.41** 0.43** 
Adjusted R
2
 0.31** 0.33** 0.34** 0.33** 0.38** 0.40** 0.42** 
95% CI for 
R
2
 
0.22, 
0.38 
0.24, 
0.41 
0.24, 
0.41 
0.24, 
0.41 
0.29, 
0.45 
0.32, 
0.48 
0.34, 
0.50 
n 342 341 341 340 340 339 338 
Missing 45 46 46 47 47 48 49 
 
* Statistically significant at p < 0.05. ** Statistically significant at p < 0.0001. 
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Table 4.4c: Results for Objective 1a.  Multiple-linear regression analysis showing the 
coefficient of determination for each model (R
2
) and regression coefficients of the cross-
sectional association between GASE scores and seven clinical aspects of epilepsy at Time 3 
(12 months post-diagnosis). 
 Regression coefficients 
 Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Intercept 0.91* 0.84* 0.72* 0.75* 0.57* 0.46* 0.41* 
Frequency of 
seizures 
0.55* 0.49* 0.50* 0.48* 0.43* 0.42* 0.35* 
Intensity of 
seizures 
Not 
included 
0.10 0.05 0.11 0.10 0.05 0.03 
Falls or 
injuries 
during 
seizures 
Not 
included 
Not 
included 
0.18 0.24* 0.21* 0.20* 0.24* 
Severity of 
the post-ictal 
period 
Not 
included 
Not 
included 
Not 
included 
-0.14 -0.12 -0.10 -0.17 
Amount of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.17* 0.01 -0.01 
Side effects of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.33* 0.25* 
Interference 
of epilepsy or 
drugs with 
daily 
activities 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.26* 
R
2
 0.32** 0.33** 0.33** 0.34** 0.35** 0.41** 0.44** 
Adjusted R
2
 0.32** 0.32** 0.33** 0.33** 0.35** 0.40** 0.43** 
95% CI for 
R
2 
0.24, 
0.40 
0.24, 
0.41 
0.25, 
0.41 
0.25, 
0.42 
0.26, 
0.43 
0.32, 
0.48 
0.34, 
0.51 
n 338 336 336 336 335 333 332 
Missing 49 51 51 51 52 54 55 
 
* Statistically significant at p < 0.05. ** Statistically significant at p < 0.0001. 
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Table 4.4d: Results for Objective 1a.  Multiple-linear regression analysis showing the 
coefficient of determination for each model (R
2
) and regression coefficients of the cross-
sectional association between GASE scores and seven clinical aspects of epilepsy at Time 4 
(24 months post-diagnosis). 
 Regression coefficients 
 Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 
Intercept 0.46* 0.41* 0.17 0.19 -0.07 -0.10 0.01 
Frequency of 
seizures 
0.80* 0.71* 0.69* 0.68* 0.61* 0.56* 0.47* 
Intensity of 
seizures 
Not 
included 
0.13* 0.03 0.12 0.10 0.09 0.12 
Falls or 
injuries during 
seizures 
Not 
included 
Not 
included 
0.36* 0.43* 0.41* 0.37* 0.14 
Severity of the 
post-ictal 
period 
Not 
included 
Not 
included 
Not 
included 
-0.17* -0.18* -0.13 -0.22* 
Amount of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.26* 0.14* 0.07 
Side effects of 
AEDs 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.20* 0.11* 
Interference of 
epilepsy or 
drugs with 
daily activities 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
Not 
included 
0.42* 
R
2
 0.56** 0.57** 0.59** 0.59** 0.63** 0.65** 0.70** 
Adjusted R
2
 0.56** 0.57** 0.58** 0.59** 0.63** 0.64** 0.69** 
95% CI for 
R
2 
0.49, 
0.63 
0.49, 
0.64 
0.51, 
0.65 
0.51, 
0.65 
0.56, 
0.69 
0.58, 
0.70 
0.63, 
0.75 
n 322 321 321 321 321 321 321 
Missing 65 66 66 66 66 66 66 
 
* Statistically significant at p < 0.05. ** Statistically significant at p < 0.0001. 
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Table 4.5: Results for Objective 1b. Spearman rank correlations of GASE scores with the 
total number of AEDs reported by neurologists at Time 1 (baseline), 2 (6 months post-
diagnosis), 3 (12 months post-diagnosis), and 4 (24 months post-diagnosis). 
 Time 1 Time 2 Time 3 Time 4 
Spearman Rho 0.18 0.32 0.36 0.37 
95% CI 0.08, 0.28 0.22, 0.41 0.26, 0.45 0.27, 0.46 
P-value 0.0005 < 0.0001 < 0.0001 < 0.0001 
 
Table 4.6: Results for Objective 1c. Comparison of mean GASE scores for patients with and 
without neurologist-reported convulsive status epilepticus (CSE) at Time 1 (baseline), 2 (6 
months post-diagnosis), 3 (12 months post-diagnosis), and 4 (24 months post-diagnosis).  
 Time 1 Time 2 Time 3 Time 4 
CSE No Yes No Yes No Yes No Yes 
N 358 18 327 16 325 14 303 11 
Mean 2.55 2.94 1.97 2.00 1.86 2.07 1.71 1.55 
SD 1.19 1.11 1.11 1.21 1.03 1.27 1.07 0.82 
Range 1-7 1-5 1-7 1-5 1-6 1-4 1-7 1-3 
t Value -1.36 -0.1 -0.76 0.51 
DF 374 341 337 312 
P-value 0.17 0.9235 0.4463 0.6093 
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Table 4.7: Results for Objective 1d. Comparison of mean GASE scores for patients with 
and without neurologist-reported exclusive nocturnal seizures at Time 1 (baseline), 2 (6 
months post-diagnosis), 3 (12 months post-diagnosis), and 4 (24 months post-diagnosis). 
 Time 1 Time 2 Time 3 Time 4 
Exclusive 
nocturnal 
seizures 
No Yes No Yes No Yes No Yes 
N 291 82 274 66 275 61 263 50 
Mean 2.70 2.15 2.05 1.65 1.92 1.64 1.78 1.36 
SD 1.22 0.98 1.16 0.83 1.08 0.82 1.12 0.63 
Range 1-7 1-5 1-7 1-4 1-6 1-4 1-7 1-4 
t Value 3.79 2.61 1.89 2.55 
DF 371 338 334 311 
P-value 0.0002 0.0094 0.0599 0.0113 
 
Table 4.8: Results for Objective 1e.  Spearman rank correlations for comparison of GASE 
scores and parents’ perception of child health in the past 4 weeks at Time 1 (baseline), 2 (6 
months post-diagnosis), 3 (12 months post-diagnosis), and 4 (24 months post-diagnosis). 
 Time 1 Time 2 Time 3 Time 4 
Spearman Rho -0.17 -0.23 -0.31 -0.34 
95% CI -0.27, -0.07 -0.33, -0.12 -0.41, -0.20 -0.45, -0.23 
P-value 0.0013 < 0.0001 < 0.0001 < 0.0001 
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Table 4.9a:  Results for Objective 2a. Distribution of GASE change scores from Time 2 (6 
months post-diagnosis) to Time 3 (12 months post-diagnosis) (n = 311).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in GASE score 
from Time 2 to Time 3 
Frequency Percent 
-4 1 0.3 
-3 5 1.6 
-2 20 6.4 
-1 66 21.2 
0 157 50.5 
1 46 14.8 
2 14 4.5 
3 1 0.3 
4 1 0.3 
Frequency Missing = 76 
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Table 4.9b: Results for Objective 2a. Distribution of absolute GASE change scores in the 
sub-samples of patients exhibiting zero change in clinical aspects of epilepsy and the 
composite score from Time 2 (6 months post-diagnosis) to Time 3 (12 months post-
diagnosis). 
Clinical aspect of 
epilepsy 
Sub-sample 
with zero 
change in 
clinical aspect  
(T2 to T3) 
Absolute change in GASE  
(from sub-samples with zero change in the clinical aspect) 
No 
change 
1- 
point 
2- 
point 
3- 
point 
4- 
point 
Frequency of seizures 
(n = 321) 
176 
118  
(67%) 
46  
(26%) 
9 
 (5%) 
3  
(1.7%) 
0 
Intensity of seizures 
(n = 319) 
170 
110  
(64.7%) 
45  
(26.5%) 
12  
(7%) 
2  
(1.2%) 
1 
(0.59%) 
Falls or injuries 
during seizures 
(n = 321) 
252 
140  
(55.6%) 
81 
(32%) 
24  
(9.5%) 
5 
(1.98%) 
2 
(0.79%) 
Severity of the post-
ictal period  
(n = 321) 
203 
120  
(59.1%) 
59  
(29%) 
19 
 (9.4%) 
3 
(1.48%) 
2 
(0.99%) 
Convulsive Status 
Epilepticus  
(n = 322) 
295  
(no at both 
times) 
144  
(48.8%) 
109 
 (37%) 
34  
(11.5%) 
6 
(2.03%) 
2 
(0.68%) 
Exclusive Nocturnal 
Seizures 
(n = 319) 
292 
148  
(50.7%) 
106 
 (36.3%) 
30 
 (10.3%) 
6 
(2.05%) 
2 
(0.68%) 
Number of AEDs 
currently (n = 318) 
268 
139  
(52%) 
99 
 (37%) 
24  
(9%) 
5 
(1.87%) 
1 
(0.37%) 
Composite score       
* Frequency + 
Intensity + Falls + 
Post-ictal + CSE + 
ENS + AEDs   
(n = 310) 
101 
74  
(73.3%) 
19  
(18.8%) 
6  
(5.9%) 
2 
(1.98%) 
0 
 
* Frequency = Frequency of seizures; Intensity = Intensity of seizures; Falls = Falls or injuries 
during seizures; Post-ictal = Severity of the post-ictal period; CSE = Convulsive status 
epilepticus; ENS = Exclusive nocturnal seizures; AEDs = Number of AEDs currently. 
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Table 4.9c: Results for Objective 2a. Distribution and direction of change in GASE scores 
for the sub-samples of patients exhibiting zero change in clinical aspects of epilepsy and the 
composite score from Time 2 (6 months post-diagnosis) to Time 3 (12 months post-
diagnosis). 
Clinical aspect of 
epilepsy 
Sub-sample 
with zero 
change in 
clinical 
aspect  
(T2 to T3) 
Direction of change in GASE scores  
(from sub-samples with zero change in the clinical aspect) 
No 
change 
Increase Decrease 
1-
point 
2-
point 
3-
point 
4-
point 
1-
point 
2-
point 
3-
point 
4-
point 
Frequency of 
seizures (n = 321) 
176 
118 
(67%) 
22 (12.5%) 36 (20.5%) 
20 2 0 0 26 7 3 0 
Intensity of seizures 
(n = 319) 
170 
110 
(64.7%) 
28 (16.5%) 32 (18.8%) 
22 5 0 1 23 7 2 0 
Falls or injuries 
during seizures 
(n = 321) 
252 
140 
(55.6%) 
47 (18.7%) 65 (25.9%) 
34 11 1 1 47 13 4 1 
Severity of the post-
ictal period  
(n = 321) 
203 
120 
(59.1%) 
33 (16.3%) 50 (24.6%) 
25 7 0 1 34 12 3 1 
Convulsive Status 
Epilepticus  
(n = 322) 
295  
(no at both 
times) 
144 
(48.8%) 
62 (21%) 89 (30%) 
46 14 1 1 63 20 5 1 
Exclusive Nocturnal 
Seizures 
(n = 319) 
292 
148 
(50.7%) 
58 (19.9%) 86 (29.5%) 
44 12 1 1 62 18 5 1 
Number of AEDs 
currently  
(n = 318) 
268 
139 
(52%) 
51 (19%) 78 (29%) 
40 10 0 1 59 14 5 0 
Composite score     
* Frequency + 
Intensity + Falls + 
Post-ictal + CSE + 
ENS + AEDs   
(n = 310) 
101 
74 
(73.3%) 
16 (15.8%) 11 (10.9%) 
10 4 2 0 9 2 0 0 
 
* Frequency = Frequency of seizures; Intensity = Intensity of seizures; Falls = Falls or injuries 
during seizures; Post-ictal = Severity of the post-ictal period; CSE = Convulsive status 
epilepticus; ENS = Exclusive nocturnal seizures; AEDs = Number of AEDs currently. 
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Table 4.9d: Results for Objective 2a. Results of the tests of stability (ICC and t-test) for 
GASE scores from Time 2 (6 months post-diagnosis) to Time 3 (12 months post-diagnosis) 
using the sub-samples of patients classified by external criteria (clinical indicators or 
composite score) as “stable” during the same time period. 
 STABILITY 
External clinical indicator 
ICC  
(95% CI) 
T-Test n 
Frequency of seizures 
0.64  
(0.54, 0.72) 
2.43 
(p = 0.02) 
176 
Intensity of seizures 
0.60  
(0.50, 0.69) 
0.62  
(p = 0.54) 
170 
Falls or injuries during seizures 
0.53 
(0.44, 0.61) 
1.64 
(p = 0.10) 
252 
Severity of post-ictal period 
0.54 
(0.43, 0.63) 
2.03 
(p = 0.04) 
203 
Convulsive status epilepticus 
(no at both times) 
0.52 
(0.43, 0.59) 
2.27 
(p = 0.02) 
295 
Exclusive nocturnal seizures 
0.55 
(0.46, 0.62) 
2.40 
(p = 0.02) 
292 
Number of AEDs currently 
0.53  
(0.42, 0.60) 
2.40 
(p = 0.02) 
268 
Composite score    
* Frequency + Intensity + Falls + 
Post-ictal + CSE + ENS + AEDs   
0.61 
(0.47, 0.72) 
1.42 
(p = 0.16) 
101 
 
* Frequency = Frequency of seizures; Intensity = Intensity of seizures; Falls = Falls or injuries 
during seizures; Post-ictal = Severity of the post-ictal period; CSE = Convulsive status 
epilepticus; ENS = Exclusive nocturnal seizures; AEDs = Number of AEDs currently. 
 
Table 4.10: Results for Objective 2b. Results of the tests of stability (ICC and t-test) for 
GASE scores from Time 2 (6 months post-diagnosis) to Time 3 (12 months post-diagnosis) 
using the sub-samples of patients classified by external criteria (parents’ perception of their 
child’s health) as “stable” during the same time period. 
 STABILITY 
External clinical indicator 
ICC  
(95% CI) 
T-Test n 
Parents’ perception of child health 
in past 4 weeks (Time 3 – Time 2) 
0.53 
(0.38, 0.65) 
1.70 
(p = 0.0918) 
115 
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Table 4.11: Distribution of GASE change scores from Time 1 (baseline) to Time 3 (6 months 
post-diagnosis) (n = 331). 
Change in GASE score 
from Time 1 to Time 3 
Frequency Percent 
-5 1 0.3 
-4 5 1.5 
-3 25 7.6 
-2 50 15.1 
-1 90 27.2 
0 117 35.4 
1 38 11.5 
2 4 1.2 
3 1 0.3 
Frequency Missing = 56 
 
Table 4.12: Results for Objective 3a. Responsiveness indices, Standardized Response Mean 
(SRM) and probability of change statistic (p) for the GASE scores at Time 1 (baseline) 
compared with Time 2 (6 months post-diagnosis), Time 3 (12 months post-diagnosis), and 
Time 4 (24 months post-diagnosis). 
GASE Scale Change Score SRM (95% CI) p (95% CI) 
Time 2-Time 1 -0.49 (-0.61, -0.37) 0.69 (0.65, 0.73) 
Time 3-Time 1 -0.58 (-0.71, -0.45) 0.72 (0.68, 0.76) 
Time 4-Time 1 -0.68 (-0.81, -0.55) 0.75 (0.71, 0.79) 
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Table 4.13: Results for Objective 3b. Spearman rank correlations for change in mean 
GASE scores and change in external criteria (clinical aspects of epilepsy or composite score) 
rated by neurologists from Time 1 (baseline) to Time 3 (12 months post-diagnosis).  
Change in clinical aspects vs. 
changes in GASE scores (T3-
T1) 
Spearman 
Rho 
95% CI P-value 
Frequency of Seizures 0.42 0.32, 0.50 < 0.0001 
Intensity of seizures 0.45 0.36, 0.53 < 0.0001 
Falls or injuries during seizures 0.22 0.11, 0.32 < 0.0001 
Severity of the post-ictal period 0.33 0.23, 0.42 < 0.0001 
Convulsive status epilepticus -0.01 -0.12, 0.09 0.80 
Exclusive nocturnal seizures -0.01 -0.12, 0.10 0.81 
Number of AEDs currently 0.10 -0.01, 0.20 0.08 
Composite score    
* Frequency + Intensity + Falls + 
Post-ictal + CSE + ENS + AEDs   
0.47 0.38, 0.56 < 0.0001 
 
* Frequency = Frequency of seizures; Intensity = Intensity of seizures; Falls = Falls or injuries 
during seizures; Post-ictal = Severity of the post-ictal period; CSE = Convulsive status 
epilepticus; ENS = Exclusive nocturnal seizures; AEDs = Number of AEDs currently. 
 
Table 4.14: Results for Objective 3c. Spearman rank correlations for change in mean GASE 
scores and change in the parents’ perception of child health from Time 1 (baseline) to Time 
3 (12 months post-diagnosis). 
Parents’ perception of change vs. 
GASE score change 
Spearman 
Rho 
95% CI P-value 
Parents’ perception of child health in 
the past 4 weeks (Time 3-Time 1) 
-0.12 -0.23, 0 0.053 
Parents’ perception of child health 
compared to 1 year ago (Time 3) 
0.24 0.12, 0.35 < 0.0001 
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Table 4.15: Results for Objective 3d. Results for the tests of responsiveness (ES, GRS, t-test) 
for GASE scores from Time 1 (baseline) to Time 3 (12 months post-diagnosis) using sub-
samples of patients classified by external criteria (clinical indicators or the composite score) 
as “changed”. The full patient sample was used to calculate AUROC of the GASE scores.   
 
RESPONSIVENESS 
“Changed” Sub-samples Full Patient Sample 
External clinical indicator ES GRS T-Test n 
AUROC 
(95% CI) 
n 
Frequency of seizures 0.72 0.84 
11.21 
(p < 0.0001) 
259 
0.67 
(0.61, 0.74) 
326 
Intensity of seizures 0.70 0.84 
10.49 
(p < 0.0001) 
242 
0.63 
(0.56, 0.69) 
325 
Falls or injuries during seizures 0.76 0.79 
6.69 
(p < 0.0001) 
98 
0.55 
(0.48, 0.63) 
326 
Severity of post-ictal period 0.77 0.69 
9.39 
(p < 0.0001) 
162 
0.59 
(0.53, 0.65) 
326 
Convulsive status epilepticus 0.67 0.69 
1.35 
(p = 0.22) 
7 
0.50 
(0.25, 0.74) 
318 
Exclusive nocturnal seizures 0.68 0.60 
3.23  
(p = 0.004) 
23 
0.51 
(0.39, 0.62) 
327 
Number of AEDs currently 0.60 0.56 
4.88 
(p < 0.0001) 
94 
0.52 
(0.45, 0.59) 
325 
Composite score       
* Frequency + Intensity + Falls + 
Post-ictal + CSE + ENS + AEDs   
0.60 0.59 
9.63 
(< 0.0001) 
284 
0.53 
(0.40, 0.67) 
302 
 
* Frequency = Frequency of seizures; Intensity = Intensity of seizures; Falls = Falls or injuries 
during seizures; Post-ictal = Severity of the post-ictal period; CSE = Convulsive status 
epilepticus; ENS = Exclusive nocturnal seizures; AEDs = Number of AEDs currently. 
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Table 4.16: Results for Objective 3e. Results for the tests of responsiveness (ES, GRS, t-test) 
for GASE scores from Time 1 (baseline) to Time 3 (12 months post-diagnosis) using sub-
samples of patients classified by external criteria (parents’ perception of their child’s 
health) as “changed”. The full patient sample was used to calculate AUROC of the GASE 
scores. 
 
RESPONSIVENESS 
“Changed” Sub-samples Full Patient Sample 
External clinical indicator ES GRS T-Test n 
AUROC 
(95% CI) 
n 
Parents’ perception of child health 
in past 4 weeks (Time 3 – Time 1)  
0.62 0.70 
7.48 
(p = 0.0001) 
172 
0.50 
(0.44, 0.57) 
274 
Parents’ perception of child health 
compared to 1 year ago (Time 3) 
0.69 0.61 
8.42 
(p < 0.0001) 
164 
0.54 
(0.47, 0.61) 
271 
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CHAPTER 5  
DISCUSSION AND CONCLUSION 
5.1 Summary and Interpretation of Findings 
This study evaluated the measurement properties of the GASE Scale using data from a 
prospective cohort study (HERQULES) that followed children with newly diagnosed 
epilepsy across Canada for two years post diagnosis. The results showed that the GASE 
Scale reflected many of the core clinical aspects that characterize epilepsy in its 
assessment of overall severity. It was also moderately capable of detecting stability 
within a 6 month time frame and responsive to changes in clinical criteria, as well as 
parents’ perception of child health over a period of 12 months.  
In the evaluation of construct validity, the moderate to strong correlations of frequency 
and intensity of seizures and interference of epilepsy or drugs with daily activities with 
GASE scores suggested that these specific elements contributed most strongly to the 
physician’s assessment of overall severity of epilepsy using the GASE Scale. This 
finding supported the hypothesis that the correlations between several clinical aspects of 
epilepsy and GASE scores would be at least moderate (r ≥ 0.3) and is consistent with 
preliminary research that tested the relationship between GASE scores and physician-
rated clinical aspects (Speechley et al., 2008). Frequency of seizures was also moderately 
correlated with GASE scores in an adult sample of patients (Wiebe et al., 2013). In 
general, the current study showed that side effects of AEDs, falls or injuries during 
seizures, and the total number of AEDs also contributed moderately to the assessment, as 
predicted in the hypotheses. However, the severity of the post-ictal period and amount of 
AEDs were less important, particularly during the first year following diagnosis. 
Although these two variables were only weakly correlated with GASE scores and did not 
support the hypothesis, they were moderately correlated with GASE scores at Time 4. As 
hypothesized, patients with exclusive nocturnal seizures scored significantly lower GASE 
severity than patients without the condition. However, contrary to the hypothesis, CSE 
did not appear to influence GASE assessment. Similarly in a recent study, patients with 
CSE had poorer HRQL independent of clinical features such as GASE severity (Ferro et 
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al., 2014). The small sample size of patients with CSE at all four time points may have 
also decreased the power of the analysis to detect a statistically significant difference in 
GASE scores between patients who had experienced CSE and those who had not. 
The magnitude of all correlations of ratings on individual clinical aspects of epilepsy with 
GASE scores increased over time. Although it is possible that physicians were influenced 
by the content in the Physician Form for their assessment of GASE severity (response 
bias), it is also possible that these clinical aspects were more important in the assessment 
of severity the longer patients had been diagnosed with epilepsy. For example, side 
effects of AEDs will have less impact on the assessment of severity at the time of 
diagnosis if physicians have not yet prescribed medication. In addition, it is possible that 
as the epilepsy syndrome and type of seizures become clearer over time, the clinical 
features pertaining to each syndrome have a more stable and stronger influence on the 
overall assessment of severity in the clinician’s mind.  
During development of the GASE Scale, preliminary validation tests found the frequency 
of seizures to be the most strongly correlated aspect (Speechley et al., 2008). Frequency 
of seizures is also recognized as a critical factor in the assessment of epilepsy (Cramer 
and French, 2001) and it is a central component in other epilepsy-related severity 
assessment instruments. In support of the hypothesis, the frequency of seizures was the 
strongest predictor of GASE scores at Times 2, 3, and 4. However, at Time 1, the 
interference of epilepsy or drugs with daily activities and the intensity of seizures were 
more strongly correlated with GASE. This discrepancy at Time 1 may reflect uncertainty 
at the time of diagnosis, where physician-rated assessments of clinical aspects and the 
GASE score were primarily based on free historical recall from parents rather than on 
direct clinical observation. By Time 2, physicians were likely more familiar with the 
presentation of their patient’s epilepsy and perhaps better able to focus on precise 
indicators of severity during a defined time frame. This could have resulted in greater 
clarity to aid diagnosis as well as a coherent assessment of severity and its elements. 
Prior to this study, all clinical aspects assessed were accepted as common characteristics 
related to the illness and its severity (Camfield and Camfield, 2002, Speechley et al., 
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2008). Results of the cross-sectional analysis did not fully support the hypotheses for 
construct validity since only a few aspects seemed to explain most of the total variation in 
GASE scores. However, overall results suggest that the GASE Scale incorporated several 
key aspects of epilepsy that are important to clinicians in their consideration of severity. 
It was also flexible to changes in the importance of different clinical criteria at different 
times in the course of the condition. These findings provide some evidence to support the 
construct validity of the physician-rated GASE Scale in a sample of children with newly 
diagnosed epilepsy in Canada. 
Parents’ perception of their child’s health did not correlate as predicted at every time 
point with the physicians’ assessment of overall severity of epilepsy. The results suggest 
that parents’ perception of child health and the physicians’ assessment of severity of 
epilepsy became more related over time. A weak correlation at Times 1 and 2 increased 
to a moderate correlation at Times 3 and 4. Although it has been documented that parents 
perceive their children’s epilepsy differently than physicians (Ryan et al., 2003), another 
explanation for the weak to moderate correlations is that parents and physicians were 
asked to rate different constructs. While parents were asked to rate their child’s health 
compared to other children his or her age within the context of a questionnaire focused on 
assessing HRQL, the GASE asked physicians to specifically rate severity of epilepsy. 
The physicians’ assessment was most likely compared to other children with epilepsy. 
Therefore, the reference populations were also different. The increase in correlation over 
time may be attributed to physicians and parents sharing their unique expertise and 
experience with each other, thereby influencing their own perceptions and broadening 
their overall understanding of childhood epilepsy (Ryan et al., 2003). Low correlations 
between parental assessment of HRQL and GASE scores may also be explained by the 
entirely different nature of the HRQL questions. One question asked about the child’s 
health in the last four weeks, and the other was a transitional question asking about health 
now compared with one year ago. The latter correlated more strongly with GASE scores 
(Table 4.14), but the interpretation of these dissimilar constructs is not straightforward.  
The minimum ICC value of 0.7 generally considered adequate to demonstrate reliability 
of an instrument (Guyatt et al., 2008, pp.257, Streiner and Norman, 2008, pp.193-4) was 
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not met for GASE Scale scores taken 6 months apart in stable patients as classified by the 
various individual clinical variables. The low to moderate stability of GASE scores was 
also shown by the t-test results, where a significant difference in mean scores was found 
for several “stable” sub-samples according to the clinical aspects. Nevertheless, the 
values of ICC ranged between 0.52 and 0.64, indicating that more than 50% of total 
variability was explained by the variability among patients. Although these results did not 
strongly support the hypothesis that GASE scores would remain stable when key clinical 
aspects of epilepsy indicated stability in patients’ epilepsy over a period of 6 months, the 
finding that the majority of patients changed by only 1-point on the GASE Scale from 
Time 2 to Time 3 provided some evidence to support stability in the GASE Scale. This 
finding further indicated that the “zero change” definition of stability used for this 
assessment may have been too restrictive. This definition provides a conservative 
estimate of stability and may not be as representative of the clinical situation when 
assessed with a single-item scale. Therefore, a broader definition of stability may be more 
meaningful to clinicians and patients, as well as improve interpretation of the reliability 
of the GASE Scale.  
During development of the GASE Scale, preliminary research showed adequate inter-
rater and test-retest reliability using a series of clinical case scenarios (Speechley et al., 
2008). In the current study, several factors may have influenced the results and decreased 
reliability. Typically in reliability assessment, observations are recorded with a shorter 
time interval, often 2 to 14 days (Streiner and Norman, 2008, pp.182). The interval for 
the current assessment of stability was limited by the data collection schedule of 
HERQULES, where the shortest interval was 6 months. During this time, patients with 
newly diagnosed epilepsy may have experienced many changes, from treatment to 
management of their daily lives. Therefore, it was not the ideal timeframe to assess 
reliability of the GASE Scale. To improve the assessment of reliability, Streiner and 
Norman recommend shortening the retest interval (Streiner and Norman, 2008, pp.197). 
Another reason for lower ICC values could be the method used for classifying patients as 
stable according to individual clinical variables. Although the ICC was larger when 
patients were classified by the composite score, the GASE Scale was designed to 
encompass all aspects of epilepsy including those that were not tested. Therefore, 
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stability in one aspect may not necessarily determine stability in overall GASE 
assessment. Other factors are likely to change even when some clinical aspects remain 
stable over time. The highest ICC demonstrated by the “stable” sub-sample according to 
frequency of seizures is consistent with the finding that it is a strong predictor of GASE 
scores and other epilepsy-related severity measures (Cramer and French, 2001). The 
observation that physicians tended to record a decrease in severity using GASE even 
when they rated individual clinical aspects as stable over time, also suggests that other 
factors independent of the key variables tested in this study influenced how physicians 
judged overall severity of epilepsy. It is also possible that over time, physicians had 
recalibrated their understanding and assessment of overall severity of epilepsy (response 
shift). The internal standards against which they evaluated severity at Time 2 may have 
been different at Time 3, thereby affecting the measurement of stability (Streiner and 
Norman, 2008, pp.124-5).  
The moderate stability of GASE scores also found in the “stable” sub-sample classified 
according to the parents’ perception of child health did not fully support the hypothesis, 
but may be attributed to the weak correlation with GASE scores shown in the assessment 
of construct validity. As mentioned previously, the viewpoints were different, and the 
questions evaluated different attributes of health or epilepsy.  
As there is no agreement over a standard measure of responsiveness (Streiner and 
Norman, 2008, pp.283), this study used an aggregate of common statistical indices to 
assess the GASE Scale. Both distribution-based and anchor-based methods suggested that 
the GASE Scale was sensitive to changes in the severity of epilepsy in children.  
In the comparison of mean change in GASE scores from baseline to 6, 12, and 24 months 
post-diagnosis, the SRMs indicated that the GASE Scale detected a moderate magnitude 
of change which corresponded with a greater than 50% probability of detecting change. 
These findings supported the hypothesis that GASE would detect statistically significant 
change and suggested that it was responsive to changes in severity of epilepsy at all three 
time intervals.  
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In the absence of a gold standard for the assessment of overall severity of epilepsy, seven 
key clinical aspects of epilepsy were selected as external criteria to compare with the 
GASE Scale on stability and change over time. The criteria were determined to be the 
most objective clinical indicators of stable severity of epilepsy as recorded in the 
Physician Form based on physician’s most recent interview with patients and parents. As 
predicted, comparison of mean change scores in the external criteria and the GASE Scale 
showed that changes in the composite score, intensity and frequency of seizures, and 
severity of the post-ictal period were moderately correlated with increases in severity of 
GASE scores from Time 1 to Time 3, with the highest correlation in the composite score. 
These clinical aspects were also the most highly correlated with GASE scores at each 
time point in the cross-sectional analysis. Contrary to the hypotheses, CSE and exclusive 
nocturnal seizure change scores were the least related with changes in GASE and were 
not found to be statistically significant. The negligible correlation may be attributed to the 
finding that GASE scores were not influenced by CSE and that few patients changed in 
their status of exclusive nocturnal seizures over time.  
The parents’ perception of change in their child’s health was analyzed using two different 
questions from the Parent’s Questionnaire and compared with GASE change scores. Both 
questions indicated that an increase in severity detected by the GASE Scale was only 
weakly correlated with the parents’ perception of their child’s health status as worsening. 
These results did not support the hypothesis. However, the weak correlations may be due 
to the same reasons why the correlation between parents’ and physicians’ perceptions 
were weak to moderate at certain time points in the cross-sectional analyses. In particular, 
the parents and physicians had different perspectives and were asked to rate similar but 
different attributes of health and epilepsy.  
In evaluating the magnitude of change detected in each of the “changed” sub-samples 
according to different clinical aspects and the composite score, the ES and GRS indicated 
that a moderate to large change was consistently detected by the GASE Scale, in support 
of the hypotheses. The large magnitude of change was estimated by GRS for the 
“changed” sub-sample as classified by both frequency and intensity of seizures. Since not 
all clinical aspects equally influence the overall assessment of severity of epilepsy, the 
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difference in effect sizes reflects the ability of the GASE Scale to respond to distinct 
changes in specific clinical elements of epilepsy. This provided sufficient evidence to 
support the responsiveness of the GASE Scale to changes in clinical aspects of epilepsy 
in children from Time 1 to Time 3 of this study.  
Further supporting the hypothesis that GASE scores would reflect the change in patients 
indicated by key clinical aspects of epilepsy, the t-test additionally showed a significant 
difference in GASE scores between the two time points, except when change was 
classified according to CSE. The low t-statistic corresponds with findings from the 
assessment of construct validity, where CSE did not appear to influence GASE scores. 
The small sample size of patients who had experienced change in CSE status (n = 7) may 
have also decreased the power of the analysis to detect change if it had occurred. Overall, 
the “changed” sub-sample based on the composite score had a smaller effect size than the 
sub-samples based on the individual clinical aspects. For the composite score, patients 
were classified as “changed” if any of the individual clinical aspects experienced change 
in score from Time 1 to Time 3, including any patients for whom there were changes in 
the number of AEDs currently. The “changed” sub-sample based on the number of AEDs 
currently showed the lowest magnitude of change in GASE over time and therefore, may 
have reduced the overall effect size detected by the composite score.  
Results for the AUROC suggested some ability of the GASE Scale to discriminate 
between “stable” and “changed” patients who were classified according to certain clinical 
criteria and the composite score. However, the low discriminatory accuracy of the GASE 
in this assessment did not support the hypotheses and may be attributed to the low 
correlation of these individual clinical aspects with GASE scores and the restrictive 
definition of “stability” or unspecific definition of “changed” patients. Although the 
selection of specific clinical criteria was informed by a paediatric neurologist and 
epileptologist, a more thorough analysis is required to assess other contributing aspects to 
severity of epilepsy and to establish precise definitions of stability and change in the 
clinical criteria as well as GASE. Considering the limitations associated with the 
methodology of this assessment of AUROC, the poor results may not provide clinically 
valuable information about the validation of the GASE Scale. It is possible that the value 
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of the AUROC would improve with clinically relevant definitions of stability and 
minimal amount of change. 
In evaluating the magnitude of change detected in the “changed” sub-samples according 
to the two questions assessing parents’ perception of child health, the ES and GRS 
indicated that a moderate to large change was detected by the GASE Scale in both sub-
samples. The t-test additionally showed a significant difference in GASE scores from the 
two time points. These results support the hypotheses and provide evidence that when 
change is perceived by parents, the GASE Scale is responsive to this change. Parents’ 
perception of their child’s health may also be a factor that was considered by physicians 
when assessing change in the overall severity of epilepsy using the GASE Scale. 
However, the minimal ability of the GASE Scale to discriminate between “stable” and 
“changed” patients according to the parents’ perception of stability and change in their 
child’s health status as shown in the small AUROC was not consistent with predictions 
and was likely affected by the same limitations surrounding the analysis of clinical 
variables and the GASE Scale. 
5.2 Study Strengths 
This study is characterized by several strengths. The data for this thesis came from a two-
year, multi-centre, prospective cohort study with a large sample size, a strong response 
rate, and high retention rates. Participating children were incident cases of epilepsy and 
represented diverse types of epilepsy syndromes. This study also addressed some of the 
limitations of past research on the validation of other measurement scales. Stability was 
assessed using the ICC statistic rather than the Pearson correlation. Streiner and Norman 
(2008, pp. 183) indicate that the Pearson correlation is a liberal measure and that the ICC 
is a better estimate of true reliability. Although no single ideal method exists to assess the 
various aspects of validity of the GASE Scale, this thesis takes advantage of several 
common statistics used in validation. While many existing scales relevant to the 
assessment of epilepsy have not assessed responsiveness to change, the validation of the 
GASE Scale involved data from four time points, enabling the analysis of the GASE 
Scale’s ability to detect change over time. Several responsiveness indices (distribution- 
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and anchor-based methods) were also reported so that results could be compared with 
other scales tested under similar circumstances. This provides further information for 
readers to decide whether the scale is effective and how it may respond under different 
study objectives.  
5.3 Study Limitations 
The current study also has a few limitations. As a secondary analysis, the data used in this 
thesis were originally collected with the primary objective to assess HRQL in children 
with epilepsy and the associated risk factors (Speechley et al., 2012). Therefore, items 
included in the questionnaires were not developed with the main goal of analyzing the 
validity of the GASE Scale. Other epilepsy-related severity assessment instruments were 
not included in the study. As a result, there were no comparisons of the GASE Scale with 
other common measures of severity of seizures or syndromes. Additionally, only the 
physicians’ and parents’ perceptions were evaluated since patients themselves were 
considered too young to accurately complete questionnaires. Since the GASE Scale was 
developed to consider all aspects of a patient’s epilepsy, clinical criteria only represent 
the clinical dimension of severity. There are many ways to define severity and although 
the clinical dimension is important for research and clinical goals, the results of this study 
show that other factors may also contribute to the physicians’ assessment of severity of 
epilepsy, such as biological, genetic, or environmental influences on severity (Stein et al., 
1987). Although ratings from several key clinical factors were compared with GASE 
scores, the limited number of criteria specific to the severity of epilepsy that was included 
in HERQULES prevented a broader analysis of construct validity. Another limitation of 
the secondary analysis is that data were collected at a minimum interval of 6 months 
which is larger than the ideal time frame for assessing the reliability of scores.  
A major challenge in the measurement of the severity of epilepsy is the absence of a 
standard definition and description of specific elements that affect its assessment. The 
literature surrounding the measurement of severity of epilepsy advocates for a simple, 
broad, and flexible instrument that incorporates all of the complex factors affecting 
severity (Cramer, 2001). Although there are several common aspects used to assess 
severity of epilepsy, there is no clear definition or outline of the appropriate elements that 
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represent and form the basis of the overall construct. Therefore, it is difficult to determine 
whether the GASE Scale (or any other scale) accurately captures the overall severity of 
epilepsy without first establishing all of the criteria that determine the severity of epilepsy 
(Aaronson et al., 2002). 
In contrast, a standard definition that outlines specific criteria may not be applicable in a 
sample of real patients because the impact of specific variables influencing the 
assessment of severity depends on the study objectives, population, and design (Stein et 
al., 1987). Without a standard definition, combining several measures may provide a 
broader evaluation of the many variables affecting the severity of epilepsy (Dunn et al., 
2004, Wagner et al., 2009). 
Validity also varies according to the population and context. As a result, the valid 
application of the GASE Scale in this study may not be applicable to all other situations 
(Beaton et al., 2001). As shown in the assessment of construct validity, certain variables 
had more influence on GASE scores at different time points. In particular, the amount of 
AEDs was not an important factor at the time of diagnosis for children with epilepsy. 
Also, it is unclear whether the moderate reliability of GASE scores was due to the 
moderate stability of the scale or a result of the particular study design. Additionally, in 
the evaluation of responsiveness to change of GASE scores, a minimal amount of change 
considered valid and important to patients in one circumstance may not be meaningful to 
another group of patients (Liang, 2000, Revicki et al., 2008). The clinical significance 
can also depend on the baseline severity level of the patient as well as other external 
factors.  
Another limitation of this study concerns the definition of stability and change. Although 
GASE scores were evaluated in sub-samples classified according to clinically important 
factors, the zero change criteria for stability was determined to be too restrictive to be 
clinically meaningful. For example, when clinical aspects indicated no change, the 
majority of patients recorded a ±1-point change in GASE scores. As the purpose of this 
study was to examine whether any amount of change could be detected by the GASE 
Scale, a minimal important change was not examined. The responsiveness indices 
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analyzed in this study (SRM, ES, GRS, and paired t-test) could not be used to assess the 
GASE Scale’s ability to detect change to varying degrees (Stratford et al., 1996). 
Therefore, the study was able to show that the GASE Scale was sensitive to changes in 
clinically important factors over time. However, the minimal degree of change on the 
GASE Scale that would translate into meaningful changes for patients and physicians in 
the sample of patients from HERQULES was not formally explored.  
The design of this study was also prone to several forms of bias. If parents could not 
accurately remember the condition of their child’s health in the past year, recall bias may 
have affected the parents’ assessment of change. Since parents were asked to rate the 
current state of their child’s health compared to the previous year, their perception of 
change may have also been strongly influenced by the perception of their child’s current 
status, which is described by the implicit theory of change (Norman et al., 1997, Streiner 
and Norman, 2008, pp. 124-5). During the two years of the study, physicians may have 
altered their internal definition of overall severity of epilepsy and the aspects influencing 
their assessment, regardless of actual changing factors affecting the severity of epilepsy 
(Streiner and Norman, 2008, pp. 124-5). For example, it is possible that after seeing the 
list of clinical aspects and the GASE Scale on the same page of the Physician Form at 
Time 1, physicians based their subsequent assessments of severity on those specific 
clinical criteria. This response shift bias further complicates the analysis of whether or 
not differences over time in the assessment of GASE scores were due to real change in 
the contributing factors affecting severity of epilepsy in children or to internal changes in 
the rater of severity.  
5.4 Future Directions 
There are several opportunities for future research to continue the ongoing process of the 
validation of the GASE Scale. Since there are many dimensions that are important in the 
assessment of severity of epilepsy, the development of a broad definition can help to 
identify specific factors related to the assessment of severity of epilepsy (Aaronson et al., 
2002). Future research could also investigate the different aspects considered by 
physicians, parents, or patients themselves. This would enable a more thorough 
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assessment of construct validity, where GASE scores are compared with other external 
criteria in different populations and situations. Another important research goal is to 
evaluate the relationship between the GASE Scale and other epilepsy-related severity 
assessment instruments such as the VA Scale, NHS3, LSSS, HASS, SSQ, and the ESSS-
Q. This may involve the inclusion of several measures in a single study evaluating 
severity in patients with epilepsy. The GASE Scale could also be compared with EEG 
data, as it is important in the clinical assessment of epilepsy. 
As the GASE Scale can be modified to assess adult patients, future researchers could also 
modify the scale to assess the severity of epilepsy from the perspective of parents and 
patients themselves. This would facilitate a direct comparison of the physicians’, parents’ 
and patients’ perspective of overall severity of epilepsy.  
To improve confidence in the ability of the GASE Scale to detect true changes over time, 
future work should also reassess the reliability of the GASE Scale within a shorter time 
frame and in patients who are stable in other aspects of epilepsy. Other tests related to 
responsiveness to change can involve studying whether the GASE Scale can detect 
different degrees of change in external criteria and to define a minimal clinically 
important difference of the GASE Scale which could add value to the finding that the 
scale is capable of detecting change. Potential studies in the future can also improve the 
understanding of the changing contribution of factors affecting the assessment of severity 
of epilepsy over time and the reasons for this change.  
Future uses of the GASE Scale may include evaluating the efficacy of treatments for 
epilepsy or the impact of AEDs, as well as the diagnosis and monitoring of severity status 
for patients with epilepsy (Aaronson et al., 2002). 
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5.5 Conclusions 
The validation of measurement tools involves an ongoing process of obtaining repeated 
evidence to verify its accuracy and reliability in measuring the intended construct in 
different populations and circumstances (Streiner and Norman, 2008, pp.250-2). Building 
on previous work to improve confidence in the GASE Scale, this study used different 
criteria and methods to evaluate construct validity, stability, and responsiveness to 
change in severity of epilepsy. Overall, this study suggested that the GASE Scale 
captured many important elements in its assessment of overall severity of epilepsy in 
children. It was also flexible to changes in the importance of different clinical criteria at 
different moments in time. In a sample of more than 300 children across Canada with 
newly diagnosed epilepsy, the GASE Scale demonstrated modest potential to detect 
stability in patients as well as responsiveness to changes over the first two-years 
following the diagnosis of epilepsy. The moderate correlations of key clinical aspects 
with GASE scores showed that the scale did not exclusively evaluate the frequency or 
intensity of seizures, which are the focus of many common measures of epilepsy. In the 
past, the frequency of seizures was the standard measure for assessing severity as well as 
the efficacy of AEDs (O'Donoghue et al., 1996). This was followed by the current trend 
of using measures that assess the severity of seizures. However, in the past few decades 
the value of a broad measure of severity of epilepsy has been recognized and is 
recommended because it can incorporate the complex dimensions of epilepsy that are 
important to clinicians and patients when describing the impact and severity of disease 
(Cramer, 2001). When the GASE Scale is used together with other measures of epilepsy 
and severity, the assessment can provide a more comprehensive evaluation of the 
multidimensional nature of epilepsy (Dunn et al., 2004, Wagner et al., 2009). This is also 
beneficial for studies interested in identifying the precise factors affecting assessment of 
severity, since the GASE Scale is a single-item scale and does not provide additional 
information on the factors influencing severity of epilepsy. 
Despite the evidence supporting the general validity of the GASE Scale, future research 
is still needed to address the limitations of the current study and to continue the process 
of validation.  
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You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley 
Materials on a stand-alone basis, or any of the rights granted to you hereunder to any other person. 
 The Wiley Materials and all of the intellectual property rights therein shall at all times remain the 
exclusive property of John Wiley & Sons Inc, the Wiley Companies, or their respective licensors, and 
your interest therein is only that of having possession of and the right to reproduce the Wiley 
Materials pursuant to Section 2 herein during the continuance of this Agreement. You agree that you 
own no right, title or interest in or to the Wiley Materials or any of the intellectual property rights 
therein. You shall have no rights hereunder other than the license as provided for above in Section 2. 
No right, license or interest to any trademark, trade name, service mark or other branding ("Marks") 
of WILEY or its licensors is granted hereunder, and you agree that you shall not assert any such 
right, license or interest with respect thereto.  
 NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF 
ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH 
RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN 
THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF 
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MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR 
PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES 
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU 
 WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement 
by you. 
 You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, 
officers, agents and employees, from and against any actual or threatened claims, demands, causes 
of action or proceedings arising from any breach of this Agreement by you.  
 IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY 
OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, 
INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR 
IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE 
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF 
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE 
(INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, 
USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT 
THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS 
LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF 
ANY LIMITED REMEDY PROVIDED HEREIN.  
 Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, 
invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible 
the same economic effect as the original provision, and the legality, validity and enforceability of the 
remaining provisions of this Agreement shall not be affected or impaired thereby.  
 The failure of either party to enforce any term or condition of this Agreement shall not constitute a 
waiver of either party's right to enforce each and every term and condition of this Agreement. No 
breach under this agreement shall be deemed waived or excused by either party unless such waiver 
or consent is in writing signed by the party granting such waiver or consent. The waiver by or 
consent of a party to a breach of any provision of this Agreement shall not operate or be construed 
as a waiver of or consent to any other or subsequent breach by such other party.  
 This Agreement may not be assigned (including by operation of law or otherwise) by you without 
WILEY's prior written consent. 
 Any fee required for this permission shall be non-refundable after thirty (30) days from receipt by the 
CCC.  
 These terms and conditions together with CCC�s Billing and Payment terms and conditions (which 
are incorporated herein) form the entire agreement between you and WILEY concerning this 
licensing transaction and (in the absence of fraud) supersedes all prior agreements and 
representations of the parties, oral or written. This Agreement may not be amended except in writing 
signed by both parties. This Agreement shall be binding upon and inure to the benefit of the parties' 
successors, legal representatives, and authorized assigns.  
 In the event of any conflict between your obligations established by these terms and conditions and 
those established by CCC�s Billing and Payment terms and conditions, these terms and conditions 
shall prevail.  
 WILEY expressly reserves all rights not specifically granted in the combination of (i) the license 
details provided by you and accepted in the course of this licensing transaction, (ii) these terms and 
conditions and (iii) CCC�s Billing and Payment terms and conditions. 
 This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was 
misrepresented during the licensing process. 
 This Agreement shall be governed by and construed in accordance with the laws of the State of New 
York, USA, without regards to such state�s conflict of law rules. Any legal action, suit or proceeding 
arising out of or relating to these Terms and Conditions or the breach thereof shall be instituted in a 
court of competent jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction of such court, 
waives any objection to venue in such court and consents to service of process by registered or 
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certified mail, return receipt requested, at the last known address of such party.  
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription journals offering 
Online Open. Although most of the fully Open Access journals publish open access articles under the terms of 
the Creative Commons Attribution (CC BY) License only, the subscription journals and a few of the Open 
Access Journals offer a choice of Creative Commons Licenses:: Creative Commons Attribution (CC-BY) 
license Creative Commons Attribution Non-Commercial (CC-BY-NC) license and Creative Commons 
Attribution Non-Commercial-NoDerivs (CC-BY-NC-ND) License. The license type is clearly identified on the 
article. 
Copyright in any research article in a journal published as Open Access under a Creative Commons License 
is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the 
original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is 
maintained and its original authors, citation details and publisher are identified as follows: [Title of 
Article/Author/Journal Title and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the 
Journal]. Links to the final article on Wiley�s website are encouraged where applicable. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and transmit an article, 
adapt the article and make commercial use of the article. The CC-BY license permits commercial and non-
commercial re-use of an open access article, as long as the author is properly attributed. 
The Creative Commons Attribution License does not affect the moral rights of authors, including without 
limitation the right not to have their work subjected to derogatory treatment. It also does not affect any other 
rights held by authors or third parties in the article, including without limitation the rights of privacy and 
publicity. Use of the article must not assert or imply, whether implicitly or explicitly, any connection with, 
endorsement or sponsorship of such use by the author, publisher or any other party associated with the 
article. 
For any reuse or distribution, users must include the copyright notice and make clear to others that the article 
is made available under a Creative Commons Attribution license, linking to the relevant Creative Commons 
web page. 
To the fullest extent permitted by applicable law, the article is made available as is and without representation 
or warranties of any kind whether express, implied, statutory or otherwise and including, without limitation, 
warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of defects, 
accuracy, or the presence or absence of errors. 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC) License permits use, distribution and 
reproduction in any medium, provided the original work is properly cited and is not used for commercial 
purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) permits use, 
distribution and reproduction in any medium, provided the original work is properly cited, is not used for 
commercial purposes and no modifications or adaptations are made. (see below) 
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Use by non-commercial users 
For non-commercial and non-promotional purposes, individual users may access, download, copy, display 
and redistribute to colleagues Wiley Open Access articles, as well as adapt, translate, text- and data-mine the 
content subject to the following conditions: 
 The authors' moral rights are not compromised. These rights include the right of "paternity" (also 
known as "attribution" - the right for the author to be identified as such) and "integrity" (the right for 
the author not to have the work altered in such a way that the author's reputation or integrity may be 
impugned).  
 Where content in the article is identified as belonging to a third party, it is the obligation of the user to 
ensure that any reuse complies with the copyright policies of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for non-commercial research and 
education purposes, a link to the appropriate bibliographic citation (authors, journal, article title, 
volume, issue, page numbers, DOI and the link to the definitive published version on Wiley Online 
Library) should be maintained. Copyright notices and disclaimers must not be deleted.  
 Any translations, for which a prior translation agreement with Wiley has not been agreed, must 
prominently display the statement: "This is an unofficial translation of an article that appeared in a 
Wiley publication. The publisher has not endorsed this translation."  
Use by commercial "for-profit" organisations 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further 
explicit permission from Wiley and will be subject to a fee. Commercial purposes include: 
 Copying or downloading of articles, or linking to such articles for further redistribution, sale or 
licensing;  
 Copying, downloading or posting by a site or service that incorporates advertising with such content;  
 The inclusion or incorporation of article content in other works or services (other than normal 
quotations with an appropriate citation) that is then available for sale or licensing, for a fee (for 
example, a compilation produced for marketing purposes, inclusion in a sales pack)  
 Use of article content (other than normal quotations with appropriate citation) by for-profit 
organisations for promotional purposes  
 Linking to article content in e-mails redistributed for promotional, marketing or educational purposes;  
 Use for the purposes of monetary reward by means of sale, resale, licence, loan, transfer or other 
form of commercial exploitation such as marketing products  
 Print reprints of Wiley Open Access articles can be purchased from: corporatesales@wiley.com  
Further details can be found on Wiley Online Library http://olabout.wiley.com/WileyCDA/Section/id-
410895.html 
Other Terms and Conditions:  
v1.9 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your 
reference. No payment is required. 
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APPENDIX D: Permission to Use Table 1.2 
JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
Dec 18, 2014 
This Agreement between Cindy Chan ("You") and John Wiley and Sons ("John Wiley and Sons") consists of your 
order details and the terms and conditions provided by John Wiley and Sons and Copyright Clearance Center. 
License Number 3532220442300 
License date Dec 18, 2014 
Licensed Content Publisher John Wiley and Sons 
Licensed Content Publication Epilepsia 
Licensed Content Title Revised terminology and concepts for organization of seizures 
and epilepsies: Report of the ILAE Commission on Classification 
and Terminology, 2005–2009 
Licensed Content Author Anne T. Berg,Samuel F. Berkovic,Martin J. Brodie,Jeffrey 
Buchhalter,J. Helen Cross,Walter Van Emde Boas,Jerome 
Engel,Jacqueline French,Tracy A. Glauser,Gary W. 
Mathern,Solomon L. Moshé,Douglas Nordli,Perrine Plouin,Ingrid 
E. Scheffer 
Licensed Content Date Feb 26, 2010 
Pages 10 
Type of use Dissertation/Thesis 
Requestor type University/Academic 
Format Print and electronic 
Portion Figure/table 
Number of figures/tables 1 
Original Wiley figure/table number(s) Table 3 
Will you be translating? No 
Title of your thesis / dissertation GLOBAL ASSESSMENT OF SEVERITY OF EPILEPSY (GASE) 
SCALE IN CHILDREN WITH EPILEPSY: CONSTRUCT VALIDITY, 
STABILITY, AND RESPONSIVENESS 
Expected completion date Dec 2014 
Expected size (number of pages) 141 
Requestor Location Cindy Chan 
----------------- 
None 
None 
-------------------- 
--------- 
Attn: Cindy Chan 
 
Billing Type Invoice 
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Billing Address Cindy Chan 
--------------------- 
None 
None 
------------------------ 
Canada 
Attn: Cindy Chan 
 
Total 0.00 CAD 
 Terms and Conditions 
 TERMS AND CONDITIONS 
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one of its group 
companies (each a"Wiley Company") or handled on behalf of a society with which a Wiley Company has 
exclusive publishing rights in relation to a particular work (collectively "WILEY"). By clicking �accept� in 
connection with completing this licensing transaction, you agree that the following terms and conditions apply 
to this transaction (along with the billing and payment terms and conditions established by the Copyright 
Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that you opened your 
Rightslink account (these are available at any time at http://myaccount.copyright.com). 
Terms and Conditions 
 The materials you have requested permission to reproduce or reuse (the "Wiley Materials") are 
protected by copyright.  
 You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone basis), non-
transferable, worldwide, limited license to reproduce the Wiley Materials for the purpose specified in 
the licensing process. This license is for a one-time use only and limited to any maximum distribution 
number specified in the license. The first instance of republication or reuse granted by this licence 
must be completed within two years of the date of the grant of this licence (although copies prepared 
before the end date may be distributed thereafter). The Wiley Materials shall not be used in any other 
manner or for any other purpose, beyond what is granted in the license. Permission is granted 
subject to an appropriate acknowledgement given to the author, title of the material/book/journal and 
the publisher. You shall also duplicate the copyright notice that appears in the Wiley publication in 
your use of the Wiley Material. Permission is also granted on the understanding that nowhere in the 
text is a previously published source acknowledged for all or part of this Wiley Material. Any third 
party content is expressly excluded from this permission. 
 With respect to the Wiley Materials, all rights are reserved. Except as expressly granted by the terms 
of the license, no part of the Wiley Materials may be copied, modified, adapted (except for minor 
reformatting required by the new Publication), translated, reproduced, transferred or distributed, in 
any form or by any means, and no derivative works may be made based on the Wiley Materials 
without the prior permission of the respective copyright owner. You may not alter, remove or 
suppress in any manner any copyright, trademark or other notices displayed by the Wiley Materials. 
You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley 
Materials on a stand-alone basis, or any of the rights granted to you hereunder to any other person. 
 The Wiley Materials and all of the intellectual property rights therein shall at all times remain the 
exclusive property of John Wiley & Sons Inc, the Wiley Companies, or their respective licensors, and 
your interest therein is only that of having possession of and the right to reproduce the Wiley 
Materials pursuant to Section 2 herein during the continuance of this Agreement. You agree that you 
own no right, title or interest in or to the Wiley Materials or any of the intellectual property rights 
therein. You shall have no rights hereunder other than the license as provided for above in Section 2. 
No right, license or interest to any trademark, trade name, service mark or other branding ("Marks") 
of WILEY or its licensors is granted hereunder, and you agree that you shall not assert any such 
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right, license or interest with respect thereto.  
 NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF 
ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH 
RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN 
THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF 
MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR 
PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES 
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU 
 WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement 
by you. 
 You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, 
officers, agents and employees, from and against any actual or threatened claims, demands, causes 
of action or proceedings arising from any breach of this Agreement by you.  
 IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY 
OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, 
INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR 
IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE 
MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF 
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE 
(INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, 
USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT 
THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS 
LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF 
ANY LIMITED REMEDY PROVIDED HEREIN.  
 Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, 
invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible 
the same economic effect as the original provision, and the legality, validity and enforceability of the 
remaining provisions of this Agreement shall not be affected or impaired thereby.  
 The failure of either party to enforce any term or condition of this Agreement shall not constitute a 
waiver of either party's right to enforce each and every term and condition of this Agreement. No 
breach under this agreement shall be deemed waived or excused by either party unless such waiver 
or consent is in writing signed by the party granting such waiver or consent. The waiver by or 
consent of a party to a breach of any provision of this Agreement shall not operate or be construed 
as a waiver of or consent to any other or subsequent breach by such other party.  
 This Agreement may not be assigned (including by operation of law or otherwise) by you without 
WILEY's prior written consent. 
 Any fee required for this permission shall be non-refundable after thirty (30) days from receipt by the 
CCC.  
 These terms and conditions together with CCC�s Billing and Payment terms and conditions (which 
are incorporated herein) form the entire agreement between you and WILEY concerning this 
licensing transaction and (in the absence of fraud) supersedes all prior agreements and 
representations of the parties, oral or written. This Agreement may not be amended except in writing 
signed by both parties. This Agreement shall be binding upon and inure to the benefit of the parties' 
successors, legal representatives, and authorized assigns.  
 In the event of any conflict between your obligations established by these terms and conditions and 
those established by CCC�s Billing and Payment terms and conditions, these terms and conditions 
shall prevail.  
 WILEY expressly reserves all rights not specifically granted in the combination of (i) the license 
details provided by you and accepted in the course of this licensing transaction, (ii) these terms and 
conditions and (iii) CCC�s Billing and Payment terms and conditions. 
 This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was 
misrepresented during the licensing process. 
 This Agreement shall be governed by and construed in accordance with the laws of the State of New 
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York, USA, without regards to such state�s conflict of law rules. Any legal action, suit or proceeding 
arising out of or relating to these Terms and Conditions or the breach thereof shall be instituted in a 
court of competent jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction of such court, 
waives any objection to venue in such court and consents to service of process by registered or 
certified mail, return receipt requested, at the last known address of such party.  
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription journals offering 
Online Open. Although most of the fully Open Access journals publish open access articles under the terms of 
the Creative Commons Attribution (CC BY) License only, the subscription journals and a few of the Open 
Access Journals offer a choice of Creative Commons Licenses:: Creative Commons Attribution (CC-BY) 
license Creative Commons Attribution Non-Commercial (CC-BY-NC) license and Creative Commons 
Attribution Non-Commercial-NoDerivs (CC-BY-NC-ND) License. The license type is clearly identified on the 
article. 
Copyright in any research article in a journal published as Open Access under a Creative Commons License 
is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the 
original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is 
maintained and its original authors, citation details and publisher are identified as follows: [Title of 
Article/Author/Journal Title and Volume/Issue. Copyright (c) [year] [copyright owner as specified in the 
Journal]. Links to the final article on Wiley�s website are encouraged where applicable. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and transmit an article, 
adapt the article and make commercial use of the article. The CC-BY license permits commercial and non-
commercial re-use of an open access article, as long as the author is properly attributed. 
The Creative Commons Attribution License does not affect the moral rights of authors, including without 
limitation the right not to have their work subjected to derogatory treatment. It also does not affect any other 
rights held by authors or third parties in the article, including without limitation the rights of privacy and 
publicity. Use of the article must not assert or imply, whether implicitly or explicitly, any connection with, 
endorsement or sponsorship of such use by the author, publisher or any other party associated with the 
article. 
For any reuse or distribution, users must include the copyright notice and make clear to others that the article 
is made available under a Creative Commons Attribution license, linking to the relevant Creative Commons 
web page. 
To the fullest extent permitted by applicable law, the article is made available as is and without representation 
or warranties of any kind whether express, implied, statutory or otherwise and including, without limitation, 
warranties of title, merchantability, fitness for a particular purpose, non-infringement, absence of defects, 
accuracy, or the presence or absence of errors. 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC) License permits use, distribution and 
reproduction in any medium, provided the original work is properly cited and is not used for commercial 
purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) permits use, 
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distribution and reproduction in any medium, provided the original work is properly cited, is not used for 
commercial purposes and no modifications or adaptations are made. (see below) 
Use by non-commercial users 
For non-commercial and non-promotional purposes, individual users may access, download, copy, display 
and redistribute to colleagues Wiley Open Access articles, as well as adapt, translate, text- and data-mine the 
content subject to the following conditions: 
 The authors' moral rights are not compromised. These rights include the right of "paternity" (also 
known as "attribution" - the right for the author to be identified as such) and "integrity" (the right for 
the author not to have the work altered in such a way that the author's reputation or integrity may be 
impugned).  
 Where content in the article is identified as belonging to a third party, it is the obligation of the user to 
ensure that any reuse complies with the copyright policies of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for non-commercial research and 
education purposes, a link to the appropriate bibliographic citation (authors, journal, article title, 
volume, issue, page numbers, DOI and the link to the definitive published version on Wiley Online 
Library) should be maintained. Copyright notices and disclaimers must not be deleted.  
 Any translations, for which a prior translation agreement with Wiley has not been agreed, must 
prominently display the statement: "This is an unofficial translation of an article that appeared in a 
Wiley publication. The publisher has not endorsed this translation."  
Use by commercial "for-profit" organisations 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further 
explicit permission from Wiley and will be subject to a fee. Commercial purposes include: 
 Copying or downloading of articles, or linking to such articles for further redistribution, sale or 
licensing;  
 Copying, downloading or posting by a site or service that incorporates advertising with such content;  
 The inclusion or incorporation of article content in other works or services (other than normal 
quotations with an appropriate citation) that is then available for sale or licensing, for a fee (for 
example, a compilation produced for marketing purposes, inclusion in a sales pack)  
 Use of article content (other than normal quotations with appropriate citation) by for-profit 
organisations for promotional purposes  
 Linking to article content in e-mails redistributed for promotional, marketing or educational purposes;  
 Use for the purposes of monetary reward by means of sale, resale, licence, loan, transfer or other 
form of commercial exploitation such as marketing products  
 Print reprints of Wiley Open Access articles can be purchased from: corporatesales@wiley.com  
Further details can be found on Wiley Online Library http://olabout.wiley.com/WileyCDA/Section/id-
410895.html 
Other Terms and Conditions:  
v1.9 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your 
reference. No payment is required. 
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